ISO_3_CODE,COUNTRYNAME,WHO_REGION,YEAR,VACCINECODE,VACCINE_DESCRIPTION,SCHEDULEROUNDS,TARGETPOP,TARGETPOP_DESCRIPTION,GEOAREA,AGEADMINISTERED,SOURCECOMMENT
ABW,Aruba,AMRO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers
ABW,Aruba,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,travellers
ABW,Aruba,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers
ABW,Aruba,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,travellers
ABW,Aruba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,healthcare workers
ABW,Aruba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M5,healthcare workers
ABW,Aruba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,healthcare workers
ABW,Aruba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"police, firemen, law-enforcement workers"
ABW,Aruba,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,females only; grade 6 primary schools
ABW,Aruba,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,females only; grade 6 primary schools
ABW,Aruba,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health and care workers
ABW,Aruba,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
ABW,Aruba,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adults with chronic conditions, residents living in long-term care facilities"
ABW,Aruba,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,students travelling abroad
ABW,Aruba,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y1,upon request
ABW,Aruba,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers to specific countries
AFG,Afghanistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Y15-Y49 (WCBA)
AFG,Afghanistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Y15-Y49 (WCBA)
AFG,Afghanistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Y15-Y49 (WCBA)
AFG,Afghanistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Y15-Y49 (WCBA)
AFG,Afghanistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Y15-Y49 (WCBA)
AGO,Angola,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact grossesse
AGO,Angola,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact grossesse
AGO,Angola,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact grossesse
AGO,Angola,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse
AGO,Angola,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse
AGO,Angola,AFRO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y49,15-49 A
AIA,Anguilla,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"adults and recommended for all health workers with no previous vaccination history (but uptake is low, it is not mandatory)"
AIA,Anguilla,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,<Y25,Single dose is offered to males and females ages 9-15+.  (one dose also offered to older females up to 25 years of age)
AIA,Anguilla,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y25,Single dose is offered to males and females ages 9-15+.  (one dose also offered to older females up to 25 years of age)
AIA,Anguilla,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-15,Single dose is offered to males and females ages 9-15+.  (one dose also offered to older females up to 25 years of age)
AIA,Anguilla,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y15,15 yrs
AIA,Anguilla,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
AIA,Anguilla,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,pregnant women
AIA,Anguilla,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6-Y1,pregnant women
AIA,Anguilla,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y4,"Children over 4 yrs of age and older with incomplete vaccinations/history of febrile seizers. Adults travelers, Adults with unknown previous vaccination history"
AIA,Anguilla,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers
ALB,Albania,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,Female from November 2022
ALB,Albania,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
AND,Andorra,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,Females; A partir del 15 de noviembre del 2023 se incluyen en la vacunación los niños tambien
AND,Andorra,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females; A partir del 15 de noviembre del 2023 se incluyen en la vacunación los niños tambien
AND,Andorra,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
AND,Andorra,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"HCW, contacts of a positive case with priority given to the less than 18 years, Pregnant women and persons immunocpmpromised"
ARE,United Arab Emirates,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,risk groups
ARE,United Arab Emirates,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,risk groups
ARE,United Arab Emirates,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,risk groups
ARE,United Arab Emirates,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,travellers
ARE,United Arab Emirates,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,travellers
ARE,United Arab Emirates,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,travellers
ARE,United Arab Emirates,EMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,school students
ARE,United Arab Emirates,EMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,school students
ARE,United Arab Emirates,EMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
ARE,United Arab Emirates,EMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y15-Y16,school students
ARE,United Arab Emirates,EMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,people 50 years old and above
ARE,United Arab Emirates,EMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M6,people 50 years old and above
ARG,Argentina,AMRO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Nacidos pretérmino con peso inferior a 1500 g y menores de 6 meses
ARG,Argentina,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Indicaciones especiales: HSH, pacientes con desórdenes de la coagulación, enfermedad hepática crónica, trabajo con el VHA en laboratorios, personal gastronómico, personal de jardines maternales que asisten a niños menores de un año de vida."
ARG,Argentina,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Indicaciones especiales: HSH, pacientes con desórdenes de la coagulación, enfermedad hepática crónica, trabajo con el VHA en laboratorios, personal gastronómico, personal de jardines maternales que asisten a niños menores de un año de vida."
ARG,Argentina,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Universal
ARG,Argentina,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Universal
ARG,Argentina,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Universal
ARG,Argentina,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Huéspedes especiales
ARG,Argentina,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,Huéspedes especiales
ARG,Argentina,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,Esquema de dos dosis (0-6) aplicado a los 11 años en mujeres nacidas a partir del año 2000 y varones nacidos a partir del año 2006.
ARG,Argentina,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Esquema de dos dosis (0-6) aplicado a los 11 años en mujeres nacidas a partir del año 2000 y varones nacidos a partir del año 2006.
ARG,Argentina,AMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Puérperas. Adultos y niños de poblaciones seleccionadas para actividades intensificadas de vacunación para contención de brote de sarampión.
ARG,Argentina,AMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Puérperas. Adultos y niños de poblaciones seleccionadas para actividades intensificadas de vacunación para contención de brote de sarampión.
ARG,Argentina,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Grupos de riesgo 1er contacto. También como parte del esquema secuencial con la PC13V para grupos de riesgo
ARG,Argentina,AMRO,2023.0,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Esquema Zagreb (0-0-7-21) para profilaxis postexposición y Profilaxis pre exposicion (0-7) para personal que trabaja con el virus en laboratorio o personas que trabajan con animales potencialmente rabiosos. Para profilaxis post-exposición cuando esté indicado su uso
ARG,Argentina,AMRO,2023.0,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,Esquema Zagreb (0-0-7-21) para profilaxis postexposición y Profilaxis pre exposicion (0-7) para personal que trabaja con el virus en laboratorio o personas que trabajan con animales potencialmente rabiosos. Para profilaxis post-exposición cuando esté indicado su uso
ARG,Argentina,AMRO,2023.0,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D21,Esquema Zagreb (0-0-7-21) para profilaxis postexposición y Profilaxis pre exposicion (0-7) para personal que trabaja con el virus en laboratorio o personas que trabajan con animales potencialmente rabiosos. Para profilaxis post-exposición cuando esté indicado su uso
ARG,Argentina,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Para quellos adultos que no acrediten esquema completo en la infancia. Si acredita esquema completo se aplica un refuerzo de DT cada 10 años.
ARG,Argentina,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M12,Para quellos adultos que no acrediten esquema completo en la infancia. Si acredita esquema completo se aplica un refuerzo de DT cada 10 años.
ARG,Argentina,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Para quellos adultos que no acrediten esquema completo en la infancia. Si acredita esquema completo se aplica un refuerzo de DT cada 10 años.
ARG,Argentina,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,1st contact,"Embarazadas a partir de la semana 20 (en cada embarazo), convivientes de RN con menos de 1500g y personal de salud que presta cuidado a niños menores de 12 meses (revacunar cada 5 años)."
ARG,Argentina,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,HW,Health workers,NATIONAL,+Y5,"Embarazadas a partir de la semana 20 (en cada embarazo), convivientes de RN con menos de 1500g y personal de salud que presta cuidado a niños menores de 12 meses (revacunar cada 5 años)."
ARG,Argentina,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,1st contact,"Embarazadas a partir de la semana 20 (en cada embarazo), convivientes de RN con menos de 1500g y personal de salud que presta cuidado a niños menores de 12 meses (revacunar cada 5 años)."
ARG,Argentina,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"1. Personal de salud sin antecedentes de infección y con serología negativa 2. Convivientes de inmunocomprometidos 3. Huéspedes en situaciones especiales: - niños con VIH con CD4 ≥ 15% o adolescentes y adultos con CD4 ≥ 200/mm³ - pacientes con deterioro de la inmunidad humoral, sin requerimiento de tratamiento sustitutivo con Inmunoglobulina  EV (ver cuadro 2) - pacientes en plan de recibir trasplante de órgano sólido (por lo menos tres semanas previas al inicio del tratamiento  inmunosupresor) - pacientes con leucemias, linfomas y otras enfermedades malignas con enfermedad en remisión y quienes hubiesen terminado el tratamiento quimioterápico al menos tres meses antes. - síndrome nefrótico"
ARG,Argentina,AMRO,2023.0,VARICELLA,Varicella vaccine,2.0,HW,Health workers,NATIONAL,+M1,"1. Personal de salud sin antecedentes de infección y con serología negativa 2. Convivientes de inmunocomprometidos 3. Huéspedes en situaciones especiales: - niños con VIH con CD4 ≥ 15% o adolescentes y adultos con CD4 ≥ 200/mm³ - pacientes con deterioro de la inmunidad humoral, sin requerimiento de tratamiento sustitutivo con Inmunoglobulina  EV (ver cuadro 2) - pacientes en plan de recibir trasplante de órgano sólido (por lo menos tres semanas previas al inicio del tratamiento  inmunosupresor) - pacientes con leucemias, linfomas y otras enfermedades malignas con enfermedad en remisión y quienes hubiesen terminado el tratamiento quimioterápico al menos tres meses antes. - síndrome nefrótico"
ARG,Argentina,AMRO,2023.0,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"1. Personal de salud sin antecedentes de infección y con serología negativa 2. Convivientes de inmunocomprometidos 3. Huéspedes en situaciones especiales: - niños con VIH con CD4 ≥ 15% o adolescentes y adultos con CD4 ≥ 200/mm³ - pacientes con deterioro de la inmunidad humoral, sin requerimiento de tratamiento sustitutivo con Inmunoglobulina  EV (ver cuadro 2) - pacientes en plan de recibir trasplante de órgano sólido (por lo menos tres semanas previas al inicio del tratamiento  inmunosupresor) - pacientes con leucemias, linfomas y otras enfermedades malignas con enfermedad en remisión y quienes hubiesen terminado el tratamiento quimioterápico al menos tres meses antes. - síndrome nefrótico"
ARG,Argentina,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"1. Personal de salud sin antecedentes de infección y con serología negativa 2. Convivientes de inmunocomprometidos 3. Huéspedes en situaciones especiales: - niños con VIH con CD4 ≥ 15% o adolescentes y adultos con CD4 ≥ 200/mm³ - pacientes con deterioro de la inmunidad humoral, sin requerimiento de tratamiento sustitutivo con Inmunoglobulina  EV (ver cuadro 2) - pacientes en plan de recibir trasplante de órgano sólido (por lo menos tres semanas previas al inicio del tratamiento  inmunosupresor) - pacientes con leucemias, linfomas y otras enfermedades malignas con enfermedad en remisión y quienes hubiesen terminado el tratamiento quimioterápico al menos tres meses antes. - síndrome nefrótico"
ARG,Argentina,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st Contact,Viajeros
ARM,Armenia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,лица с повышенным риском заболевания по схеме 0-1-6 месяцев
ARM,Armenia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,лица с повышенным риском заболевания по схеме 0-1-6 месяцев
ARM,Armenia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,лица с повышенным риском заболевания по схеме 0-1-6 месяцев
ARM,Armenia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y14,только девочкам  в возрасте 14 лет- две дозы (вторая доза через 6 месяцев после первой)
ARM,Armenia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,только девочкам  в возрасте 14 лет- две дозы (вторая доза через 6 месяцев после первой)
ARM,Armenia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"15 до 45 лет -девочки и юноши, а также женщины и мужчины- три дозы ( 0,2,6 месяцев- интервал  между первой и третьей дозой 6 месяцев)"
ARM,Armenia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"15 до 45 лет -девочки и юноши, а также женщины и мужчины- три дозы ( 0,2,6 месяцев- интервал  между первой и третьей дозой 6 месяцев)"
ARM,Armenia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15-Y45,"15 до 45 лет -девочки и юноши, а также женщины и мужчины- три дозы ( 0,2,6 месяцев- интервал  между первой и третьей дозой 6 месяцев)"
ARM,Armenia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y26-Y30,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y36-Y40,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y46-Y50,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y56-Y60,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y66-Y70,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,Y76-Y80,Женщины и мужчины от 26 лет через каждые 10 лет
ARM,Armenia,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y15-Y16,"Лицам с 15 лет до 25 лет, с 26 лет получают только АДС-М"
ARM,Armenia,EURO,2023.0,TULAREMIA,Tularemia vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,только юноши допризывного возраста 17 лет и лицам с повышенным риском заболевания и по эпидпоказаниям с 7-лет
ATG,Antigua and Barbuda,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y5,5yrs
ATG,Antigua and Barbuda,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,M18
ATG,Antigua and Barbuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Adults who didn't receive their vaccine as infants, dialysis patients, hospital staff, medical and nursing students"
ATG,Antigua and Barbuda,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y13,"females and males; aged 9-13 years x2 doses, aged 14-26 years x3 doses (+Y1 for older age group)"
ATG,Antigua and Barbuda,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"females and males; aged 9-13 years x2 doses, aged 14-26 years x3 doses (+Y1 for older age group)"
ATG,Antigua and Barbuda,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,BOTH,HPV administered to females and males,NATIONAL,+Y1,"females and males; aged 9-13 years x2 doses, aged 14-26 years x3 doses (+Y1 for older age group)"
ATG,Antigua and Barbuda,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
ATG,Antigua and Barbuda,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,sickle cell disease
ATG,Antigua and Barbuda,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,sickle cell disease
ATG,Antigua and Barbuda,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,sickle cell disease
ATG,Antigua and Barbuda,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,Vaccine given to risk groups >=2 as recommended by the doctor via medical Benefits (eg those with sickle cell disease diabetes ect)
ATG,Antigua and Barbuda,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
AUS,Australia,WPRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M18,"Aboriginal and Torres Strait Islander people in Queensland, Northern Territory, Western Australia and South Australia"
AUS,Australia,WPRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y4,"Aboriginal and Torres Strait Islander people in Queensland, Northern Territory, Western Australia and South Australia"
AUS,Australia,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,Refugee and humanitarian entrants
AUS,Australia,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y13,"Single dose, school grade 7 or age equivalent, all genders"
AUS,Australia,WPRO,2023.0,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M2,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023.0,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M4,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023.0,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M6,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023.0,MEN_B,Meningococcal B vaccine,4.0,RISKGROUPS,Risk group(s),SUBNATIONAL,M12,Aboriginal and Torres Strait Islander children. 3rd dose at M6 given to Aboriginal and Torres Strait Islander children with specified medical risk conditions
AUS,Australia,WPRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y70,<=Y70 given to adults 70 years and over (not including Aboriginal and Torres Strait Islander adults).
AUS,Australia,WPRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"M6 given to Aboriginal and Torres Strait Islander children in four regions (Queensland, Northern Territory, Western Australia and South Australia)"
AUS,Australia,WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,>=Y50 for Aboriginal and Torres Strait Islander adults (Indigenous adults)
AUS,Australia,WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Y4 for all children with specified medical risk conditions
AUS,Australia,WPRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y70-Y79,and includes time limited catch up program for 71-79 year olds until 31 Oct. 2023
AUS,Australia,WPRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,CATCHUP_A,Catch-up adults,NATIONAL,Y71-Y79,Time limited catch up program for 71-79 year olds until 31 Oct. 2023
AUT,Austria,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7-Y15,Free catch up until Y14
AUT,Austria,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,<Y21,Females and males; free catch up until Y21 sing 01.02.2023
AUT,Austria,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y21,Females and males; free catch up until Y21 sing 01.02.2023
AUT,Austria,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,Females and males
AUT,Austria,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
AUT,Austria,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
BDI,Burundi,AFRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,12-23 mois
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1er contact grossesse - femmes en âge de procrées
BDI,Burundi,AFRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,voyageurs
BEL,Belgium,EURO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,"Y5-Y6 in Wallonia, Y6 in Flanders"
BEL,Belgium,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,1st contact,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"First target group: recommended for newborns of HBsAg+ mothers, half an adult dose, at birth. Second target group: catch-up vaccination for children who weren't vaccinated with Hexyon (schedule and dose varying according to age). Third target group: it is recommended for healthcare workers to be vaccinated against hep B in case they were not vaccinated with the combination vaccine as a child. For them, the vaccine is not reimbursed but costs will usually be covered by the employer."
BEL,Belgium,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y14,"Y12 in Flanders, Y13-Y14 in Wallonia. For both males and females."
BEL,Belgium,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Y12 in Flanders, Y13-Y14 in Wallonia. For both males and females."
BEL,Belgium,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"The guidelines recommend vaccination for those ≥65 years of age. This age group takes priority group for receiving influenza vaccine; the guidelines also mention explicitly that, thereafter and depending on the availability of the vaccine, the flu vaccine is useful for healthy persons aged 50 and older."
BEL,Belgium,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,CATCHUP_C,Catch-up children,NATIONAL,<M18,vaccination x3 doses with 1 month interval (<18 months) in case no hexavalent is given)
BEL,Belgium,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,vaccination x3 doses with 1 month interval (<18 months) in case no hexavalent is given)
BEL,Belgium,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),3.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,vaccination x3 doses with 1 month interval (<18 months) in case no hexavalent is given)
BEL,Belgium,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Asylumnseekers asap after arrival: <5 months normal schedule, >5 months catch-up vaccination"
BEL,Belgium,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"During 2022, following the outbreak, it was possible for at risk groups to get vaccinated (full NITAG recommendation: https://www.hgr-css.be/file/download/8fe2ee8e-2d1b-42cb-b633-347398576d66/hGTUOQaHTrGqDcF6XmGLVzTuq9LSbnRlW7sP3RQ3d.pdf). The Flemish regional government decided to stop the vaccination campaign after December 2022 and in 2023 it was not possible to get the mpox vaccine in Flanders, but preventive vaccination was still possible in Wallonia and Brussels for high risk groups."
BEL,Belgium,EURO,2023.0,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"Different schedule depending on age, risk factors and which vaccines were given in the past. Please find the guidelines here: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220908_css-9674_pneumo_vweb.pdf"
BEL,Belgium,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"Different schedule depending on age, risk factors and which vaccines were given in the past. Please find the guidelines here: https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/20220908_css-9674_pneumo_vweb.pdf"
BEL,Belgium,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y25,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",3.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,+Y10,Adults Y25 and booster every 10 years after that. Pregnant women (each pregnancy) and their close environment (cocoon vaccination)
BEL,Belgium,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14-Y16,Y14 in Flanders and Y15-Y16 in Wallonia
BEN,Benin,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
BEN,Benin,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
BEN,Benin,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
BEN,Benin,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
BEN,Benin,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
BFA,Burkina Faso,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Filles de 9 ans
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y2,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BFA,Burkina Faso,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y2,1er contact grossesse - femmes enceintes et femmes en âge de reproduction
BGD,Bangladesh,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y49,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGD,Bangladesh,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Recommended from 15-49 years of age (WCBA) and all pregnant women without previous Td vaccination receive two doses of Td vaccine in one month interval
BGR,Bulgaria,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y13,9 valent vaccine administered; females only aged 10-13 years in line with National program for primary prophylaxis of cervical cancer 2021-2024
BGR,Bulgaria,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,9 valent vaccine administered; females only aged 10-13 years in line with National program for primary prophylaxis of cervical cancer 2021-2024
BGR,Bulgaria,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >65 years
BHR,Bahrain,EMRO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Infants born to parents (or other household close contact) originally from TB endemic areas and with current smears positive of pulmonary TB
BHR,Bahrain,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Children with contraindications or allergic to Pertussis component of the vaccine
BHR,Bahrain,EMRO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y5,Routine childhood vaccine  given to hildren at age of 4-5 years (preschool entry)
BHR,Bahrain,EMRO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Routine childhood vaccine given at age of 6 months and at the age of 18 months
BHR,Bahrain,EMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y12,Completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year
BHR,Bahrain,EMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,Y13,Completion of 2 doses of HepA vaccine checked for school students at 12 and 13 years as last school catch-up campaign done in 2016/17 academic year
BHR,Bahrain,EMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,"Given as single dose for >5 years children with sickle cell disease, anatomical and/or surgical asplenia, post bone marrow transplant, certain cancer after finishing treatment"
BHR,Bahrain,EMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y13,"Started administration of the vaccine to target group (boys and girls aged 12-13 years) as part of school vaccination campaign since October 2023. In addition, the vaccine is also available in the private sector for people requesting it."
BHR,Bahrain,EMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6-M12,"Started administration of the vaccine to target group (boys and girls aged 12-13 years) as part of school vaccination campaign since October 2023. In addition, the vaccine is also available in the private sector for people requesting it."
BHR,Bahrain,EMRO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Immunocompromised and their households
BHR,Bahrain,EMRO,2023.0,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Immunocompromised and their households
BHR,Bahrain,EMRO,2023.0,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Immunocompromised and their households
BHR,Bahrain,EMRO,2023.0,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Immunocompromised and their households
BHR,Bahrain,EMRO,2023.0,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,Immunocompromised and their households
BHR,Bahrain,EMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y5-Y50,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Routine childhood vaccine given at 2 months, 4 months of age and the last dose (booster) at 15 months. Additional dose is given at 6 months of age for certain high risk groups. A single dose for adults at age of >=50 years and for high risk groups at age 5-50 years if unvaccinated before."
BHR,Bahrain,EMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Routine vaccine for those at age of 65 years and above.  Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years."
BHR,Bahrain,EMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Routine vaccine for those at age of 65 years and above.  Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years. for certain risk categories revaccination dose after 5 years"
BHR,Bahrain,EMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,"Routine vaccine for those at age of 65 years and above.  Also, given to high risk groups from age of 2 years and above as a single dose and for certain risk categories revaccination dose given after 5 years. for certain risk categories revaccination dose after 5 years"
BHR,Bahrain,EMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,>Y65,Others at-risk persons
BHR,Bahrain,EMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y13,Students at schools
BHR,Bahrain,EMRO,2023.0,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Travellers, certain at risk groups"
BHR,Bahrain,EMRO,2023.0,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y2,"Travellers, certain at risk groups"
BHS,Bahamas,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BHS,Bahamas,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,Travellers
BHS,Bahamas,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BHS,Bahamas,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,Travellers
BHS,Bahamas,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y12,"Females and males, children aged 9-12 years"
BHS,Bahamas,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Females and males, children aged 9-12 years"
BHS,Bahamas,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
BHS,Bahamas,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,Adults 50years and older with chronic conditions; children with sickle cell disease and elderly clients 65 years and older
BHS,Bahamas,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,Adults 50years and older with chronic conditions; children with sickle cell disease and elderly clients 65 years and older
BHS,Bahamas,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
BHS,Bahamas,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y12,and at 1st contact for antenatal women
BHS,Bahamas,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BLR,Belarus,EURO,2023.0,AP,aP (acellular pertussis) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2-M18,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6,Применяется также для вакцинации детей в возрасте 6 лет на ряду с АДС-М
BLR,Belarus,EURO,2023.0,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"дети, имеющие медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2-M18,"Применяется у детей в возрасте М2-М18, имеющих медицинские противопоказания к введению вакцин, содержащих цельноклеточный коклюшный компонент"
BLR,Belarus,EURO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y4,"Дети, ранее не получившие профилактические прививки против гемофильной инфекции, до достижения ими возраста 5 лет в соответствии с инструкцией по медицинскому применению, прилагаемой к иммунобиологическому лекарственному средству, и имеющие одно из следующих заболеваний или состояний: хронический гепатит; цирроз печени; хронические заболевания почек, сердца и легких; иммунодефицитные состояния; муковисцидоз"
BLR,Belarus,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=65 years
BLR,Belarus,EURO,2023.0,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023.0,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023.0,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLR,Belarus,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Дети в возрасте 2, 4 и 12 месяцев; <5 лет с конкретными хроническими состояниями / заболеваниями"
BLZ,Belize,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",6.0,RISKGROUPS,Risk group(s),NATIONAL,Y12,Recommended for children with contraindication to pertussis containing vaccine
BLZ,Belize,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Children 18 months and 48 months
BLZ,Belize,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Children 18 months and 48 months
BLZ,Belize,AMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"Only one dose is administered since May 2023, to school children in Std 4 class. males and females 9-14 years. School based program but also administered in clinic settings as necessary"
BLZ,Belize,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Unexposed and exposed  infants at 2M and 4M and also for HIV exposed infants and children at M6, M18, Y4, Y12"
BLZ,Belize,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"Unexposed and exposed  infants at 2M and 4M and also for HIV exposed infants and children at M6, M18, Y4, Y12"
BLZ,Belize,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,"Unexposed and exposed  infants at 2M and 4M and also for HIV exposed infants and children at M6, M18, Y4, Y12"
BLZ,Belize,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),6.0,RISKGROUPS,Risk group(s),NATIONAL,Y12,"Unexposed and exposed  infants at 2M and 4M and also for HIV exposed infants and children at M6, M18, Y4, Y12"
BLZ,Belize,AMRO,2023.0,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023.0,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023.0,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023.0,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023.0,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,Environmental health program to exposed individuals
BLZ,Belize,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y12,Children in Std 6 (age 12) given a booster dose
BMU,Bermuda,AMRO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,On request for residents from endemic areas
BMU,Bermuda,AMRO,2023.0,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023.0,CHOLERA,Cholera vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+W2,Specific travel requirement for Raleigh International
BMU,Bermuda,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BMU,Bermuda,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6-M12,Travellers
BMU,Bermuda,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BMU,Bermuda,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6-M12,Travellers
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"occupational (health care workers, police and corrections), high risk adults, travellers"
BMU,Bermuda,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,High risk adults for revaccination
BMU,Bermuda,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,"females and males; x2 doses for <15 years, x3 doses for >15 years, and also available for other adults upon request"
BMU,Bermuda,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6-M12,"females and males; x2 doses for <15 years, x3 doses for >15 years, and also available for other adults upon request"
BMU,Bermuda,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65+
BMU,Bermuda,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Unvaccinated travellers to high risk areas
BMU,Bermuda,AMRO,2023.0,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers to high-risk areas
BMU,Bermuda,AMRO,2023.0,JE_INACTD,JE-Inact (Japanese Encephalitis inactivated) vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+D28,Travellers to high-risk areas
BMU,Bermuda,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Adolescents, and travellers to high-risk areas"
BMU,Bermuda,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,High risk adults
BMU,Bermuda,AMRO,2023.0,RABIES,Rabies vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Prevention for travellers at risk of exposure
BMU,Bermuda,AMRO,2023.0,RABIES,Rabies vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+D7,Prevention for travellers at risk of exposure
BMU,Bermuda,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y19,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y10,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y19,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y10,"Every 10 years to travellers, occupational hazard workers, adults"
BMU,Bermuda,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact pregnancy
BMU,Bermuda,AMRO,2023.0,TYPHOID_CONJ,Typhoid conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BMU,Bermuda,AMRO,2023.0,TYPHOID_CONJ,Typhoid conjugate vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y3,Travellers
BMU,Bermuda,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers
BMU,Bermuda,AMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y50,on referral
BMU,Bermuda,AMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,on referral
BOL,Bolivia (Plurinational State of),AMRO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18-M23,Menores de 5 año
BOL,Bolivia (Plurinational State of),AMRO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Menores de 5 año
BOL,Bolivia (Plurinational State of),AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Personal de salud, Enfermos Cronicos >=A7"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,"A niñas de 10 años, con dosis única"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BOL,Bolivia (Plurinational State of),AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"De 07 a 49 años hombres y mujeres, incluye embarazadas"
BRA,Brazil,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis)
BRA,Brazil,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis)
BRA,Brazil,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis)
BRA,Brazil,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression"
BRA,Brazil,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y19,special population; only in reference centers for special immunobiologicals
BRA,Brazil,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y19,special population; only in reference centers for special immunobiologicals
BRA,Brazil,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y26,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months)"
BRA,Brazil,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab
BRA,Brazil,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M9,patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab
BRB,Barbados,AMRO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9,Infants of parents that travel to countries with a high burden of tuberculosis
BRB,Barbados,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,CATCHUP_C,Catch-up children,NATIONAL,Y5-Y7,Children who missed their DTP at Y4.5
BRB,Barbados,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children who have a history of seizures
BRB,Barbados,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4.5,Children who have a history of seizures
BRB,Barbados,AMRO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Infants of HIV positive mothers
BRB,Barbados,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,As per request. Travellers and those on humanitarian missions.
BRB,Barbados,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,As per request. Travellers and those on humanitarian missions.
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"As per request. Medical and nursing students, HCWs and travellers on humanitarian missions"
BRB,Barbados,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y11,"Females and males; class 4's (Y10-Y11) 1st dose Form 1's (Y11), 1 dose administration approval was granted in November 2022"
BRB,Barbados,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,HW,Health workers,NATIONAL,1st contact,HCW
BRB,Barbados,AMRO,2023.0,VARICELLA,Varicella vaccine,2.0,HW,Health workers,NATIONAL,+W6,HCW
BRB,Barbados,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers to YF endemic countries
BRN,Brunei Darussalam,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,females; in school year 7
BRN,Brunei Darussalam,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,females; in school year 7
BRN,Brunei Darussalam,WPRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=60 years old
BTN,Bhutan,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
BTN,Bhutan,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
BTN,Bhutan,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BTN,Bhutan,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women 1st dose at first contact, 2nd dose after one month interval"
BWA,Botswana,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y13,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"Females; standard 5 school students, 9-13 years out of school"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"1st contact pregnancy, pregnant women, WCBA"
BWA,Botswana,AFRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,as needed for special persons (i.e. travellers)
BWA,Botswana,AFRO,2023.0,YF,YF (Yellow fever) vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y10,as needed for special persons (i.e. travellers)
CAF,Central African Republic,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes - 1er contact grossesse
CAF,Central African Republic,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes - 1er contact grossesse
CAN,Canada,AMRO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"Given in provinces/territories: x4 doses at M2, M4, M6, M18 in SK, MB, ON, NB, NS, NL, NT, NU; x1 dose at M18 in BC, AB, PE, YT; x1 dose at M12 in QC"
CAN,Canada,AMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y13,"females and males; 2nd dose 6 months after the 1st dose; x2 in gr.6 in BC, AB, SK, MB, PE, NL, YT, NU; x2 in gr.7 in NS, NB; ON; 1x in 4th yr primary school + 1x in 3rd yr secondary school in QC and catch-up in 3rd year secondary school in QC; x2 9-14yrs, x3 15+yrs in NT"
CAN,Canada,AMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y16,"females and males; 2nd dose 6 months after the 1st dose; x2 in gr.6 in BC, AB, SK, MB, PE, NL, YT, NU; x2 in gr.7 in NS, NB; ON; 1x in 4th yr primary school + 1x in 3rd yr secondary school in QC and catch-up in 3rd year secondary school in QC; x2 9-14yrs, x3 15+yrs in NT"
CAN,Canada,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons >=Y65
CAN,Canada,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,"Schedule information was collected for healthy, previously immunized adults. Given as one dose in all jurisdictions at 65yrs+, except NU. In NU, one dose given to those 50+. In YK, given to all those 65+ and all residents of extended or intermediate care facilities and high-risk individuals."
CAN,Canada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,"Schedule information was collected for healthy, previously immunized adults. Given in provinces/territories every 10 yr in BC, SK, MB, ON, NB, NS, YT, NU; x1 in at 50 yrs in QC"
CAN,Canada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+Y10,"Schedule information was collected for healthy, previously immunized adults. Given in provinces/territories every 10 yr in BC, SK, MB, ON, NB, NS, YT, NU; x1 in at 50 yrs in QC"
CAN,Canada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,SUBNATIONAL,Y15,Given in 3rd year of high school in QC
CAN,Canada,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,SUBNATIONAL,+Y10,"Schedule information was collected for healthy, previously immunized adults. Given with each pregnancy in BC and QC; Given every 10 years and each pregnancy in AB, PE, NL, and NT; One booster dose per adult lifetime and each pregnancy in SK, MB, ON, NB, NS, YT, and NU."
CAN,Canada,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,SUBNATIONAL,1st contact,"Schedule information was collected for healthy, previously immunized adults. Given with each pregnancy in BC and QC; Given every 10 years and each pregnancy in AB, PE, NL, and NT; One booster dose per adult lifetime and each pregnancy in SK, MB, ON, NB, NS, YT, and NU."
CAN,Canada,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,B_ADO_W,General/routine,SUBNATIONAL,Y11-Y16,"Given in provinces/territories: x1 in gr.9 in BC, AB, PE, NL, YT; x1 in gr.8 in SK; x1 in gr.7 in NB, NS, NT; x1 gr.6 in NU; x1 in gr.8 or 9 in MB; x1 at Y14-Y16 in ON"
CAN,Canada,AMRO,2023.0,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,"Given in provinces/territories: between Y4-Y6 in BC, SK, MB, ON, QC, NS, NL, NT, YT, NU (DTaPHibIPV sub in NL, NT if shortage); between Y4-Y5 in PE; at Y4 in AB, NB; and in province: QC catch-up in 3rd year secondary school"
CAN,Canada,AMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,>=Y60,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CAN,Canada,AMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,SUBNATIONAL,>=Y60,"Schedule information was collected for healthy, previously immunized adults. Given 2X in provinces: ON (65 to 70), PEI (60 and older), YT(65 to 79) and QC (80years and older) - 1st dose: Y60+/Y65to70/Y80+/Y65to79, 2nd dose: Y60+/Y65to70/Y80+/Y65to79"
CHE,Switzerland,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,if mother is HBA1c-pos
CHE,Switzerland,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y14,Females and males
CHE,Switzerland,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
CHE,Switzerland,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M1,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6-M10,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y6,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M1,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6-M10,"All persons who are regularly in forested areas, except in Geneva and Ticino Cantons"
CHE,Switzerland,EURO,2023.0,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y14,Vaccination only recommended if no previous natural infection
CHE,Switzerland,EURO,2023.0,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y14,Vaccination only recommended if no previous natural infection
CHE,Switzerland,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M2,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHE,Switzerland,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHE,Switzerland,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHE,Switzerland,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"All persons Y65+, Immunocompromised persons from age 50Y, and severely immunocompromised persons from age 18+"
CHL,Chile,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Hombre sexo con hombre, trabajadores sexuales, Personas viviendo con VIH, victimas de violencia sexual, Personas que ingresan a diálisis, Personas con infección por virus hepatitis C, profesionales y técnicos del área de la salud (público), vacunación especial, Ley Ricarte Soto, Personas privadas por libertad, Profesionales y técnicos del área de salud, y personal que desarrolle labores de atención de salud directa a pacientes, todos pertenecientes a establecimientos de salud de los Servicios de Salud del país, experimentales y de la Atención Primaria de Salud Municipal"
CHL,Chile,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"Se administra a niñas y niños de:  4° básico (9 años); niñas  5° básico (10 años) En niñas y niños desde los 9 a los 13 años el intervalo es de 12 meses y desde los 14 años en adelantes el esquema es 0,2,6 meses. El año 2020 los niños que iniciaron su esquema el 2019 completaran con 2° dosis cuando cursen 5° básico(10 años)"
CHL,Chile,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y10,"Se administra a niñas y niños de:  4° básico (9 años); niñas  5° básico (10 años) En niñas y niños desde los 9 a los 13 años el intervalo es de 12 meses y desde los 14 años en adelantes el esquema es 0,2,6 meses. El año 2020 los niños que iniciaron su esquema el 2019 completaran con 2° dosis cuando cursen 5° básico(10 años)"
CHL,Chile,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Prematuros: adicional al esquema nacional de niños, solo a prematuros se administra una tercera dosis a los 6 meses"
CIV,Côte d'Ivoire,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,filles de 9 ans; le vaccin HPV chez les jeunes filles de 9 ans s'administre en une seule dose depuis septembre 2023 en cote D'ivoire
CIV,Côte d'Ivoire,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,filles de 9 ans; le vaccin HPV chez les jeunes filles de 9 ans s'administre en une seule dose depuis septembre 2023 en cote D'ivoire
CIV,Côte d'Ivoire,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
CIV,Côte d'Ivoire,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
CMR,Cameroon,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"Filles et Garçons de 9 ans; Depuis 2023, le vaccin contre le HPV est administré en dose unique et désormais administré aux filles et aux garçons"
CMR,Cameroon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+M12,1er contact grossesse - femmes enceintes
CMR,Cameroon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+M12,1er contact grossesse - femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
COD,Democratic Republic of the Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
COG,Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes - 1er contact grossesse
COG,Congo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes - 1er contact grossesse
COK,Cook Islands,WPRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,HPV to Females; 9 years (2 doses)
COK,Cook Islands,WPRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,HPV to Females; 9 years (2 doses)
COK,Cook Islands,WPRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M6-M12,During measles outbreak at M6-M12
COL,Colombia,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y5,Se aplica en población hasta los 6 años de edad y los que tienen contraindicación para recibir DPT  con el mismo esquema de DPT
COL,Colombia,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Se aplica  a víctimas de violencia sexual sin importar la edad de la víctima a Nivel Nacional . Se aseguran 3 dosis 0, 1m y 6 m. El esquema de vacunación esta incluido a cargo del sistema de riesgos profesionales (Administradora de riesgos laborales)."
COL,Colombia,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Se aplica  a víctimas de violencia sexual sin importar la edad de la víctima a Nivel Nacional . Se aseguran 3 dosis 0, 1m y 6 m. El esquema de vacunación esta incluido a cargo del sistema de riesgos profesionales (Administradora de riesgos laborales)."
COL,Colombia,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Se aplica  a víctimas de violencia sexual sin importar la edad de la víctima a Nivel Nacional . Se aseguran 3 dosis 0, 1m y 6 m. El esquema de vacunación esta incluido a cargo del sistema de riesgos profesionales (Administradora de riesgos laborales)."
COL,Colombia,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y17,"La vacuna es aplicada solo a mujeres que cumplan los 9 años a 17 años, con dos dosis de vacuna. El periodo de aplicación de las dosis de la vacuna es 0 meses y la segunda dosis a los seis meses. El 1 d eoctubre de 2023, se cambia el esquema de dos dosis de vacuna a una dosis y se incluye a niños de 9 años de edad"
COL,Colombia,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"La vacuna es aplicada solo a mujeres que cumplan los 9 años a 17 años, con dos dosis de vacuna. El periodo de aplicación de las dosis de la vacuna es 0 meses y la segunda dosis a los seis meses. El 1 d eoctubre de 2023, se cambia el esquema de dos dosis de vacuna a una dosis y se incluye a niños de 9 años de edad"
COL,Colombia,AMRO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,Se realizo la aplicacion de esta vacuna en un estudio Clinico que se dividio en Inmediato y tardio de fabricante. Se aplico a poblacion de 18 anos con vulnerabilidad.
COL,Colombia,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6-Y59,"Los grupos a vacunar en en el país fueron: colombianos que van al exterior y solicitan la vacuna a libre demanda , así como en la detección de susceptibles de 11 a 49 o hasta 59 años, y durante las actividades de bloqueo, intensificación y barrido documentado en el proceso de control del brote de Sarampión, dosis cero población de 6 a 11 meses de edad, profesionales de la salud en el país."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,HW,Health workers,NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,HW,Health workers,NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Se utiliza para proteger a los adolescentes y a los adultos contra tétanos como la difteria. Es utilizada para la aplicación de dosis anti tetánica y diftérico a mujeres en embarazo. Igualmente se utiliza a pacientes de accidente tetánico como a personas contacto de pacientes sospechosos de difteria para el control de brotes y en MRV en búsquedas activas comunitarias a adolescentes y adultos que en la vigilancia epidemiológica luego de evaluar el riesgo de la población; se decida aplicar un bloqueo con vacuna ante eminente brote de Difteria, así como a trabajadores de la salud entre otros."
COL,Colombia,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,"Se aplica en población desde los 7 años de edad que tienen contraindicación para recibir DPT con el mismo esquema y en mujeres embarazadas desde la semana 26 de gestación, así como en niños que presentaron reacción a la Pentavalente"
COM,Comoros,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
COM,Comoros,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
COM,Comoros,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
COM,Comoros,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
COM,Comoros,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
CPV,Cabo Verde,AFRO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Enfants
CPV,Cabo Verde,AFRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,"Filles de 10 ans, premier contact"
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Femme enceintes et adultes
CPV,Cabo Verde,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Femme enceintes et adultes
CRI,Costa Rica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Se aplica esquema a adultos de riesgo que no cuenten con el antecedente
CRI,Costa Rica,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,Se aplica desde el 2019 a todas las niñas de 10 años
CRI,Costa Rica,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Se aplica desde el 2019 a todas las niñas de 10 años
CRI,Costa Rica,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,1 dosis única a todo adulto de 60 años o más
CRI,Costa Rica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y20,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,Se aplica una Td cada 10 años a partir de los 10 años de edad cumplidos
CRI,Costa Rica,AMRO,2023.0,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Se aplica una dosis de refuerzo de Tetravalente a los 4 años de edad
CUB,Cuba,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Hepatitis B 20mcg Grupo de riesgos
CUB,Cuba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Hepatitis B 20mcg Grupo de riesgos
CUB,Cuba,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Hepatitis B 20mcg Grupo de riesgos
CUB,Cuba,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Hijos de madre positiva al antigeno de la hepatitis B
CUB,Cuba,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Hijos de madre positiva al antigeno de la hepatitis B
CUW,Curaçao,AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,healthcare workers
CUW,Curaçao,AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,healthcare workers
CUW,Curaçao,AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,healthcare workers
CUW,Curaçao,AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,at risk persons
CUW,Curaçao,AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,at risk persons
CUW,Curaçao,AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,at risk persons
CUW,Curaçao,AMRO,2019.0,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,1 dose to travellers going to risk countries
CYM,Cayman Islands,AMRO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,2nd booster Y4-6
CYM,Cayman Islands,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,International travelers (including students going to college)
CYM,Cayman Islands,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6-M12,International travelers (including students going to college)
CYM,Cayman Islands,AMRO,2023.0,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Unimmunized international travelers
CYM,Cayman Islands,AMRO,2023.0,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",2.0,TRAVELLERS,Travellers,NATIONAL,+M1,Unimmunized international travelers
CYM,Cayman Islands,AMRO,2023.0,HEPA_HEPB,"Hepatitis A, Hepatitis B vaccine",3.0,TRAVELLERS,Travellers,NATIONAL,+M6-M12,Unimmunized international travelers
CYM,Cayman Islands,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=M12,Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M
CYM,Cayman Islands,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M18,Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M
CYM,Cayman Islands,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=M12,Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M
CYM,Cayman Islands,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6-M18,Unimmunized children from countries with Hepatitis A on schedule or international travelers >=12M
CYM,Cayman Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W4,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"at risk adults, healthcare workers and unimmunized persons"
CYM,Cayman Islands,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y12,Females
CYM,Cayman Islands,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females
CYM,Cayman Islands,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
CYM,Cayman Islands,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,International travelers as booster dose
CYM,Cayman Islands,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Given only to students going abroad to study or at risk individuals e.g. persons with Sickle Cell Anaemia
CYM,Cayman Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W6,"Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster"
CYM,Cayman Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster"
CYM,Cayman Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Upon first contact, +6W, +6M for unimmunization persons 7 years and older. Adults as booster"
CYM,Cayman Islands,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14-Y16,Yr 10 & 11 High Schools
CYM,Cayman Islands,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,unimmunized international travelers single dose
CYM,Cayman Islands,AMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M2-M6,Adults age 60 and older and other risk adults
CYM,Cayman Islands,AMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,Adults age 60 and older and other risk adults
CYM,Cayman Islands,AMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2-M6,Adults age 60 and older and other risk adults
CYM,Cayman Islands,AMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Adults age 60 and older and other risk adults
CYP,Cyprus,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,Both females and males
CYP,Cyprus,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Both females and males
CYP,Cyprus,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CYP,Cyprus,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Adult booster doses every 10 years
CZE,Czechia,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Administrated during the first month of life in cases indicated by health professionals (indications are based on legislation)
CZE,Czechia,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administrated to newborns of HBsAg positive mothers
CZE,Czechia,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y13,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5-M13,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y13,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,2 and 4 valent vaccine administered; females and males
CZE,Czechia,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,6.0,ADULTS,Adults,NATIONAL,Y25,"Regular booster vaccination every 10-15 years in adult population, therefore 6th dose is in Y25"
DEU,Germany,EURO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y4,"There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"1) Newborns of seropositive women within 12 hours postpartum, together with Hepatitis B immunoglobulin 2) Newborns of mothers whose HBsAg status is unknown and in whom serological testing is not possible before or immediately after delivery. 3) People at risk of severe hepatitis B because of an existing or expected immunodeficiency or immunosuppression, or other pre-existing diseases, for example: HIV-positive or hepatitis C-positive individuals, and patients on haemodialysis. 4) People at increased risk of non-occupational exposure, for example: people in contact with HBsAg carriers in the family or flat share, people at high risk of acquiring hepatitis B through sexual contact, injecting drug users, prison inmates, and psychiatric inpatients."
DEU,Germany,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y15-Y17,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y15-Y17,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y15-Y17,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"2, 4 and 9 valent vaccines in use. Two vaccine doses for females and males at least 5 months apart. In the case of a catch-up series starting at an age of 15 years or older or a vaccination interval of less than 5 months between the 1st and 2nd dose, a 3rd dose is necessary. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,MEN_C_CONJ,Meningococcal C conjugate vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,Catch-up is recommended up until and including 17 years of age
DEU,Germany,EURO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. The first MMR dose can be administered from 9 months of age in specific circumstances (forthcoming admission or visit to a community facility, e.g. Kindergarten, day care facility for children), in this case, the second MMR dose should be given as early as possible in the second year of life. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,MMRV,"MMRV (Measles, mumps, rubella and varicella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. The first MMR dose can be administered from 9 months of age in specific circumstances (forthcoming admission or visit to a community facility, e.g. Kindergarten, day care facility for children), in this case, the second MMR dose should be given as early as possible in the second year of life. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Two doses for men who have sex with men (MSM) and are >= 18 years of age and frequently change sexual partners (for people who have been vaccinated against smallpox in the past, a single vaccine dose is sufficient)."
DEU,Germany,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Two doses for men who have sex with men (MSM) and are >= 18 years of age and frequently change sexual partners (for people who have been vaccinated against smallpox in the past, a single vaccine dose is sufficient)."
DEU,Germany,EURO,2023.0,PCV_15_VALENT,PCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y17,"Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis."
DEU,Germany,EURO,2023.0,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y4,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023.0,PCV10,PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y4,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age."
DEU,Germany,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"10 and 13 valent vaccines in use. There should be an interval of at least 6 months between the last and the preceding dose. For premature babies (born before completed 37 weeks of pregnancy), 4 vaccine doses at the ages of 2, 3, 4 and 11 months are recommended. Catch-up is recommended up to and including 4 years of age. Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis."
DEU,Germany,EURO,2023.0,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"1) One dose of PCV20 for all people aged >= 60 years. 2) One dose of PCV20 for adults >= 18 years at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 3) Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 4) One dose of PCV20 for people performing professional activities such as welding or separating metals leading to exposure to metal smoke, including metal-oxidic welding smoke."
DEU,Germany,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y17,"1) One dose of PCV20 for all people aged >= 60 years. 2) One dose of PCV20 for adults >= 18 years at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 3) Sequential vaccination with PCV13 or PCV15, followed by PPSV23 after 6 –12 months, for children and adolescents 2-17 years of age at increased health risk as a result of congenital or acquired immunodeficiencies or other chronic diseases, or anatomical and foreign-material associated risks for pneumococcal meningitis. 4) One dose of PCV20 for people performing professional activities such as welding or separating metals leading to exposure to metal smoke, including metal-oxidic welding smoke."
DEU,Germany,EURO,2023.0,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,W12-W32,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023.0,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,W12-W32,"1 and 5 valent vaccines in use. First vaccine dose as early as the age of 6 weeks. Depending on the vaccine used, 2 (monovalent) or 3 (pentavalent) vaccine doses at an interval of at least 4 weeks. The series should preferably be completed by 16 weeks of age (monovalent) or 20-22 weeks of age (pentavalent). In case of catch-up, the first dose must be administered by 12 weeks of age and the last dose by 24 weeks of age (monovalent) or 32 weeks of age (pentavalent)."
DEU,Germany,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,"1) Td booster vaccination every 10 years. 2) Next due Td vaccination requires one dose as a Tdap or, in the case of a respective indication, as a Tdap-IPV combination vaccination."
DEU,Germany,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,"1) One dose of Tdap for all adults instead of next Td booster. 2) One dose of Tdap for pregnant women at the beginning of the 3rd trimester (from the 28th week of pregnancy). In case of an increased probability for premature birth, vaccination should be administered during the 2nd trimester. This vaccination should be administered in every pregnancy, regardless of the interval to previously administered pertussis vaccinations."
DEU,Germany,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y8,Catch-up is recommended up until and including 8 years of age
DEU,Germany,EURO,2023.0,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,Catch-up is recommended up until and including 17 years of age
DEU,Germany,EURO,2023.0,VARICELLA,Varicella vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y17,"MMR and monovalent varicella vaccine is preferably administered as two separate injections due to higher rates of febrile seizures following immunization with MMRV, MMRV is preferably administered as the second dose. Catch-up is recommended up until and including 17 years of age."
DEU,Germany,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DEU,Germany,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,>=Y60,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DEU,Germany,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y50,"Two doses for 1) all adults >= 60 years of age. 2) adults >= 50 years of age in case of increased health risk resulting from an underlying disease, for example: congenital or acquired immunodeficiency or immunosuppression; HIV infection; Rheumatoid arthritis; Systemic lupus erythematosus; Chronic inflammatory bowel disease; Chronic obstructive pulmonary disease or bronchial asthma; Chronic renal insufficiency; Diabetes mellitus."
DJI,Djibouti,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Femmes enceintes
DJI,Djibouti,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Femmes enceintes
DJI,Djibouti,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Femmes enceintes
DJI,Djibouti,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes
DJI,Djibouti,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes
DMA,Dominica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y3,Children with Seizure disorder from birth who cannot have DPT/Penta
DMA,Dominica,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,1.0,B_2YL_W,General/routine,NATIONAL,M18,Children 18M and 3 years
DMA,Dominica,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,2.0,B_CHILD_F,General/routine,NATIONAL,Y3,Children 18M and 3 years
DMA,Dominica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M5,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Unimmunized adults including health care workers. Health care workers also receive a 4th dose as a booster
DMA,Dominica,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y12,Introduced in October 2019; females and males; and a 3rd dose given if older than 15 years
DMA,Dominica,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older adults 65 years and older
DMA,Dominica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M5,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10-Y12,"Students moving on to high school in grade 6; and all other persons if not covered dose one, +W4-W6, and +M6"
DMA,Dominica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M5,Unimmunized adults including pregnant women
DMA,Dominica,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Travellers to endemic countries
DNK,Denmark,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others)"
DNK,Denmark,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others)"
DNK,Denmark,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"risk groups (lives in a household with or is a sexual partner of a person with chronic hepatitis b, IV abuser, people with hepatitis C, down syndrome and others)"
DNK,Denmark,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Neonates of HBsAG positive mothers
DNK,Denmark,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Neonates of HBsAG positive mothers
DNK,Denmark,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Neonates of HBsAG positive mothers
DNK,Denmark,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Neonates of HBsAG positive mothers
DNK,Denmark,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<=Y18,free vaccination up to the age of 18
DNK,Denmark,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5-M13,"Females only up until August 2019; from September 2019 programme expanded to cover males born after July 2007 - 1st dose between Y12-Y14, second dose more than +M5 but less than +M13 (free vaccination up to the age of 18)."
DNK,Denmark,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y14,"Females only up until August 2019; from September 2019 programme expanded to cover males born after July 2007 - 1st dose between Y12-Y14, second dose more than +M5 but less than +M13 (free vaccination up to the age of 18)."
DNK,Denmark,EURO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Recommended for all non-immune adults. Free of charge from April 1, 2018. Women of childbearing age not immune to Rubella demonstrated by antibody measurement. Given in the form of a single MFR."
DNK,Denmark,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"MSM receiving PrEP for HIV. MSM who are not receiving PrEP against HIV, but meet the criteria for this. MSM with risk behavior within the last 12 weeks, Women or trans people who are part of the same networks as MSM at high risk and with a similar contact pattern."
DNK,Denmark,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,"MSM receiving PrEP for HIV. MSM who are not receiving PrEP against HIV, but meet the criteria for this. MSM with risk behavior within the last 12 weeks, Women or trans people who are part of the same networks as MSM at high risk and with a similar contact pattern."
DNK,Denmark,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Risk groups not for free but a smaller co-payment
DNK,Denmark,EURO,2023.0,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,specific risk groups
DNK,Denmark,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Risk groups. If PCV13 is administrated 1st, 1st dose of PPV is at an interval of 8 weeks. A temporary vacination offer for everyone over 65 in the period of April 2020 until 31.12.2022. In 2023 it has become a recommended vaccine for certain risk groups but with a smaller co-payment"
DNK,Denmark,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y6,"Risk groups. If PCV13 is administrated 1st, 1st dose of PPV is at an interval of 8 weeks. A temporary vacination offer for everyone over 65 in the period of April 2020 until 31.12.2022. In 2023 it has become a recommended vaccine for certain risk groups but with a smaller co-payment"
DOM,Dominican Republic,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Menores de un año solo a falta de Penta, refuerzos a los 18 meses y 4 años."
DOM,Dominican Republic,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Trabajadores de la salud, enfermos crónicos e inmunosuprimidos"
DOM,Dominican Republic,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,Sólo vacunación en niñas de 9 a 14 años.
DOM,Dominican Republic,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,2 años y más. Bloqueos alrededor de casos de EFE
DOM,Dominican Republic,AMRO,2023.0,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023.0,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023.0,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023.0,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023.0,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,Post-Exp. Mordedura por Animal Rabioso /desc
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema, mujeres embarazadas para completar o iniciar esquema recomendado, dosis de refuerzo cada 10 años."
DOM,Dominican Republic,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,Y dosis de refuerzo cada 10 años. Para niños que no tienen ninguna dosis de vacuna o no han completado su esquema
DOM,Dominican Republic,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y1-Y59,"Viajeros de países endémicos de fiebre amarilla. Excluye embarazadas, menores de un año, inmunosuprimidos, 60 años y más."
ECU,Ecuador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Personas viviendo con VIH, personal de salud, Personas privadas de la libertad, trabajadores sexuales y otros grupos de riesgos - Conservando los intervalos de 0, 1 mes, 6 meses"
ECU,Ecuador,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrasado de vacuna Pentavalente: a población de 1 a 5 años. Conservando los intervalos de 0 mes, 2 meses 4 meses"
ECU,Ecuador,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M2,"Esquema atrasado de vacuna Pentavalente: a población de 1 a 5 años. Conservando los intervalos de 0 mes, 2 meses 4 meses"
ECU,Ecuador,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,"Esquema atrasado de vacuna Pentavalente: a población de 1 a 5 años. Conservando los intervalos de 0 mes, 2 meses 4 meses"
ECU,Ecuador,AMRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,niñas
ECU,Ecuador,AMRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,niñas
ECU,Ecuador,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=65 years
ECU,Ecuador,AMRO,2023.0,IPV_FRAC,IPVf (Inactivated polio vaccine fractional dose),1.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrasado fIPV1, fIPV2 dosis fraccionadas aplicadas en esquemas tardíos en edades simples de 1 a 5 años"
ECU,Ecuador,AMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y2-Y7,Esquema atrasado de Niños de dos a siete años de edad
ECU,Ecuador,AMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,Esquema atrasado de Niños de dos a siete años de edad
ECU,Ecuador,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y8-Y49,1er contacto viajeros de 8 a 49 años de edad
ECU,Ecuador,AMRO,2023.0,OPV,OPV (Oral polio vaccine),1.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023.0,OPV,OPV (Oral polio vaccine),2.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023.0,OPV,OPV (Oral polio vaccine),3.0,CATCHUP_C,Catch-up children,NATIONAL,Y1-Y5,"Esquema atrazado bOPV 2, bOPV 3,bOPV 4, dosis aplicadas en esquemas tardíos en edades simples de 1 a 5 años completando estado vacunal"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Población de 16 a 49 años de edad, incluyendo embarazadas, según esquema de vacunación"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
ECU,Ecuador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Población de 16 a 49 años de edad, incluyendo embarazadas, segun esquema de vacunacion"
EGY,Egypt,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,high-risk groups
EGY,Egypt,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,high-risk groups
EGY,Egypt,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,high-risk groups
EGY,Egypt,EMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,cases having previous adverse events following pertussis vaccination
EGY,Egypt,EMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
EGY,Egypt,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y7-Y8,school children
EGY,Egypt,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y9-Y10,school children
EGY,Egypt,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,women in childbearning age
EGY,Egypt,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,women in childbearning age
EGY,Egypt,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,women in childbearning age
EGY,Egypt,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,women in childbearning age
EGY,Egypt,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,women in childbearning age
ERI,Eritrea,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females 9 years - 14 years
ERI,Eritrea,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females 9 years - 14 years
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Females 14-45 years (women of child bearing age)
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ERI,Eritrea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Td vaccine is administered to specific target groups, that is female adolescents, and adults (WCBA) including pregnant women on a routine basis. Most of the target groups receive and complete their Td vaccination at school and for those out school females they are welcomed and given vaccination at health facilities or during outreach visits to communities. Moreover pregnant women are vaccinated during antenatal visits if they had not started or completed their Td vaccination status early or before they get pregnant."
ESP,Spain,EURO,2023.0,DTAPHEPBIPV,DTaP-HepB-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,SUBNATIONAL,Y6,Cohorts (prior to 2016) left from the old vaccination schedule (the current one is from 2016)
ESP,Spain,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administered only for newborns of mothers with AgHBs+
ESP,Spain,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too-"
ESP,Spain,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too-"
ESP,Spain,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y26,Risk groups (all regions)
ESP,Spain,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,>Y26,Risk groups (all regions)
ESP,Spain,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,>Y26,Risk groups (all regions)
ESP,Spain,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school)"
ESP,Spain,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school)"
ESP,Spain,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too-"
ESP,Spain,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"2, 4, 9 valent vaccines administered; females only at 12 yrs or 6th grade (regions that immunize at school) -since 2023 in males too-"
ESP,Spain,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y26,Risk groups (all regions)
ESP,Spain,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1-M2,Risk groups (all regions)
ESP,Spain,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Risk groups (all regions)
ESP,Spain,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,Risk groups (all regions)
ESP,Spain,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Risk groups (all regions)
ESP,Spain,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65-Y80,65 years old; 2nd dose administered +6 months at lease
ESP,Spain,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M6,65 years old; 2nd dose administered +6 months at lease
ESP,Spain,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,>=Y60,For specific risk groups
EST,Estonia,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Birth dose for risk group newborns (newborn of HIV-positive or untested mother), and vaccination for children with contraindication to pertussis component, children unvaccinated/partially vaccinated against HepB"
EST,Estonia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y12,females; catch-up for 2021-2023
EST,Estonia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,females; catch-up for 2021-2023
EST,Estonia,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=65 years
EST,Estonia,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),2.0,RISKGROUPS,Risk group(s),NATIONAL,M4.5,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,Y2,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
EST,Estonia,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,Y6-Y7,"Children with contraindication to pertussis component, and >7 years x3 doses if incomplete vaccination/unvaccinated"
ETH,Ethiopia,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females
ETH,Ethiopia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,CBAW (15-49Y)
ETH,Ethiopia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,CBAW (15-49Y)
FIN,Finland,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y7,Children <7 yrs at high risk of tuberculosis
FIN,Finland,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y18,Catch-up for all under 18 years of age or those in high school or vocational school to start series or complement series.
FIN,Finland,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y5,"For children <5 years at high risk of severe pneumococcal disease, and after stem cell transfusion"
FIN,Finland,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y45,"Boosters at Y45, Y65, and >65 years every 10th year"
FIN,Finland,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y65,"Boosters at Y45, Y65, and >65 years every 10th year"
FIN,Finland,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,"Boosters at Y45, Y65, and >65 years every 10th year"
FIN,Finland,EURO,2023.0,VARICELLA,Varicella vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,Y1.5-Y11,2nd dose catch up: children 1.5-11Y who haven´t had chickenpox
FJI,Fiji,WPRO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<M12,and catch-up until 12 months
FJI,Fiji,WPRO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y8,and catch-up until 8 years
FJI,Fiji,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Medical, nursing students, all healthcare workers"
FJI,Fiji,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W6,"Medical, nursing students, all healthcare workers"
FJI,Fiji,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+W14,"Medical, nursing students, all healthcare workers"
FJI,Fiji,WPRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M12,"Pre-term babies are ""special"" booster at 12 months with MR1"
FJI,Fiji,WPRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y8-Y13,Females; class 8
FJI,Fiji,WPRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females; class 8
FJI,Fiji,WPRO,2023.0,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y2,and catch-up until 2 years
FRA,France,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Professionnal at risk, adults at risk"
FRA,France,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M12,"Professionnal at risk, adults at risk"
FRA,France,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Health professionnels
FRA,France,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health professionnels
FRA,France,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Health professionnels
FRA,France,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Professionnal at risk (fireman, secourists)"
FRA,France,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Professionnal at risk (fireman, secourists)"
FRA,France,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Professionnal at risk (fireman, secourists)"
FRA,France,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Babies born to a mother infected with hepatitis B
FRA,France,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y14,"Femmes et hommes 11-14 ans: 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu’à l’âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d’autres hommes."
FRA,France,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Femmes et hommes 11-14 ans: 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu’à l’âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d’autres hommes."
FRA,France,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,and risk groups between 2-65 years
FRA,France,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y65,risk groups between 2-65 years
FSM,Micronesia (Federated States of),WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y11,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
FSM,Micronesia (Federated States of),WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"Target to only female only those in grade school (5 graders in primary schools both in public and private) girls ages 10 and 11 year old, those who sign consent form only in participating schools across the country"
GAB,Gabon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Femmes enceintes
GAB,Gabon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes
GAB,Gabon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Femmes enceintes
GAB,Gabon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Femmes enceintes
GAB,Gabon,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Femmes enceintes
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,D28,"At birth to infants in areas of the country with TB incidence >= 40/100,000 or with a parent or grandparent born in a high incidence country"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y16,<16 years in clinical risk groups including haemophilia and chronic liver disease. See pg 6 onwards of The Green Book: https://www.gov.uk/government/publications/hepatitis-a-the-green-book-chapter-17
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y15,Y1 to Y15 in clinical risk groups including haemophilia and chronic liver disease. See pg 6 onwards of The Green Book: https://www.gov.uk/government/publications/hepatitis-a-the-green-book-chapter-17
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Schedule varies according to risk factors. Babies born to hepatitis B infected mothers receive monovlanet vaccine at birth, 4 weeks and 1 year in addition to  3 doses of hexavalent vaccine as part of the routine infant programme. Clinical risk groups (such as chronic liver disease, chronic kidney disease stage 4 or 5 and haemophilia) also eligible for Hep B vaccination. Schedule varies depending on risk. See pg. 8 onwards of The Green Book chapter: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,W4,"Schedule varies according to risk factors. Babies born to hepatitis B infected mothers receive monovlanet vaccine at birth, 4 weeks and 1 year in addition to  3 doses of hexavalent vaccine as part of the routine infant programme. Clinical risk groups (such as chronic liver disease, chronic kidney disease stage 4 or 5 and haemophilia) also eligible for Hep B vaccination. Schedule varies depending on risk. See pg. 8 onwards of The Green Book chapter: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y1,"Schedule varies according to risk factors. Babies born to hepatitis B infected mothers receive monovlanet vaccine at birth, 4 weeks and 1 year in addition to  3 doses of hexavalent vaccine as part of the routine infant programme. Clinical risk groups (such as chronic liver disease, chronic kidney disease stage 4 or 5 and haemophilia) also eligible for Hep B vaccination. Schedule varies depending on risk. See pg. 8 onwards of The Green Book chapter: https://www.gov.uk/government/publications/hepatitis-b-the-green-book-chapter-18"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25-Y45,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,ADULTS,Adults,NATIONAL,Y25-Y45,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y25-Y24,3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,<Y25,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y25,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12-Y13,Administered to both females and males. Single dose given at Y12-Y13.  Catch-up for eligible young people available up to Y25; For men only: 1 dose for immunocompetent GBMSM aged less than 25 years from 1 Sept 23; 2 doses for Immunocompetent GBMSM aged 25 up to and including 45 years. 3 doses for immunosuppressed and or know to be HIV-positive GBMSM aged 25 years up to and including 45 years.
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,<Y25,Catch-up available to Y25
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,<Y25,Catch-up available to Y25
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Individuals from 2 years of age who are at increased risk of invasive meningococcal infection with asplenia, splenic dysfunction or complement disorder (including those on or to commence complement inhibitor treatment such as eculizumab). If first diagnosed or presenting under 1 year of age, to be immunised according to the routine immunisation schedule. Number of doses/schedule depends on age. More information on pg 7 of The Green Book chapter: https://assets.publishing.service.gov.uk/media/628363d6e90e071f62029bb9/Meningococcal-greenbook-chapter-22_17May2022.pdf"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,"Risk groups Y2-Y65; and all persons >Y65. PCV13 in adults is limited to those with  ""severe immunocompromise including bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO) ”. See page 8 of the pneumococcal chapter of the Green Book: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y65,"Risk groups Y2-Y65; and all persons >Y65. PCV13 in adults is limited to those with  ""severe immunocompromise including bone marrow transplant patients, patients with acute and chronic leukaemia, multiple myeloma or genetic disorders affecting the immune system (such as IRAK-4, NEMO) ”. See page 8 of the pneumococcal chapter of the Green Book: https://www.gov.uk/government/publications/pneumococcal-the-green-book-chapter-25"
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M6-M12,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y50,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GBR,United Kingdom of Great Britain and Northern Ireland,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W8,"Programme expansion from Sept 23 and move to 2 doses of Shingrix vaccine. Severely immunocompromised eligible from Y50 with 2nd dose after 8 weeks. Immunocompetent cohort - reduction from 70 to 60 years of age. Phased implementation in age reduction over 10 year period. Phase 1: 1 September 2023 to 31 August 2028, individuals turning 70 and 65 on or after 1 Sept 23. Phase 2: 1 Sept 2023 to 31 August 2033, individuals turning 65 and 60 years of age. Immunocompetent schedule: 2 doses with 2nd dose 6 to 12 months after first."
GEO,Georgia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,>Y18,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M3-M6,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M3-M6,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y18,"Defense, security and on emergency situations response service employees;  in a penitentiary institution working staff;  High risk group of hepatitis B infection (dialysis patients, hemophiliacs, injecting drug users, MSM, HIV/AIDS and hepatitis C patients, medical personnel, students of medical institutions, family members of hepatitis B infected persons, B A person exposed to a source of hepatitis B infection, persons involved in hepatitis B diagnostic services;"
GEO,Georgia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y12,"Females and males; Females national introduction from August 2019, males from July 2023"
GEO,Georgia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Females and males; Females national introduction from August 2019, males from July 2023"
GEO,Georgia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y13-Y46,"Clearning rounds of human papillomavirus vaccine in girls aged 13-46 years and 13-26 boys (A two-dose vaccination course (0-6 months) applies to the population aged 9-14 years; At the age of 15-45, the course of vaccination is three doses 0-2-6 months.)"
GEO,Georgia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2-M6,"Clearning rounds of human papillomavirus vaccine in girls aged 13-46 years and 13-26 boys (A two-dose vaccination course (0-6 months) applies to the population aged 9-14 years; At the age of 15-45, the course of vaccination is three doses 0-2-6 months.)"
GEO,Georgia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Clearning rounds of human papillomavirus vaccine in girls aged 13-46 years and 13-26 boys (A two-dose vaccination course (0-6 months) applies to the population aged 9-14 years; At the age of 15-45, the course of vaccination is three doses 0-2-6 months.)"
GEO,Georgia,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons aged 60 and older
GEO,Georgia,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,for vaccination against pneumococcal infection of persons aged 65 years and older and beneficiaries of day-night specialized institutions (shelters) for the elderly with chronic diseases (hypertension; ischemic heart disease; diabetes; pcode; asthma and other forms of respiratory failure);
GHA,Ghana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,15-49 years
GHA,Ghana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,15-49 years
GHA,Ghana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,15-49 years
GHA,Ghana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,15-49 years
GHA,Ghana,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,15-49 years
GIN,Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact grossesse
GIN,Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact grossesse
GIN,Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact grossesse
GIN,Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse
GIN,Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse
GMB,Gambia,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,"from October 2019: females; grade 3, grade 4-8 multi-cohort, 9-14 years out of school"
GMB,Gambia,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+Y1,"from October 2019: females; grade 3, grade 4-8 multi-cohort, 9-14 years out of school"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Y15-Y49, pregnant and post-partum mothers"
GMB,Gambia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Y15-Y49, pregnant and post-partum mothers"
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes en âge de procréer - 1er contact grossesse
GNB,Guinea-Bissau,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes en âge de procréer - 1er contact grossesse
GNQ,Equatorial Guinea,AFRO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,NIÑOS SUPERVIVIENTES Y DE 12 - 23 MESES
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GNQ,Equatorial Guinea,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,MUJERES EMBARAZADAS Y EN EDAD DE PROCREAR - 1ER CONTACTO CON LA EMBARAZADA
GRC,Greece,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Only for neonates that belong to high risk groups
GRC,Greece,EURO,2023.0,DTAP,DTaP (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15-M18,Either DtaP or other combination vaccine
GRC,Greece,EURO,2023.0,DTAP,DTaP (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Either DtaP or other combination vaccine
GRC,Greece,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,High-risk groups
GRC,Greece,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,High-risk groups
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"High risk groups; MSM, drug users, people with multiple sex partners/ STD/ end stage renal disease/ chronic liver disease/diabetes mellitus/ people at high risk to be exposed to blood or biological fluids (ie health workers)/ travellers visiting countries with intermediate to high prevalence of chronic HBV infection"
GRC,Greece,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,HepB is given to all infants either at M2 or HepB is given at birth if the mother is HbsAg(+) or if the status of HbsAg is unknown
GRC,Greece,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y11,"Males and Females routine vaccination between 9-18 years. Initiation of vaccination ≥15 years: 3 doses (0M, +1–2M, +6M)."
GRC,Greece,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Males and Females routine vaccination between 9-18 years. Initiation of vaccination ≥15 years: 3 doses (0M, +1–2M, +6M)."
GRC,Greece,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Females and males belonging to high-risk groups between 18-26 years
GRC,Greece,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y18-Y26,Females and males belonging to high-risk groups between 18-26 years
GRC,Greece,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Females and males belonging to high-risk groups between 18-26 years
GRC,Greece,EURO,2023.0,INFLUENZA_PEDIATRIC,Pediatric seasonal influenza vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>M6,Children in high risk groups and with chronic conditions
GRC,Greece,EURO,2023.0,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,"Y19-Y64 high risk groups, and all adults  ≥Y65"
GRC,Greece,EURO,2023.0,PCV20,PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y19-Y64,"Y19-Y64 high risk groups, and all adults  ≥Y65"
GRC,Greece,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,≥Y2 -Y18 children who belong to high risk groups
GRC,Greece,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Td/Tdap every 10Y
GRC,Greece,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y18-Y25,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",3.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,+Y10,"Y18-Y25 (Tdap/Tdap-IPV), Td/Tdap every 10Y"
GRC,Greece,EURO,2023.0,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",1.0,ADULTS,Adults,NATIONAL,Y18-Y25,Y18-Y25 (Tdap/Tdap-IPV)
GRC,Greece,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60-Y75,"ZVL ≥Y60 -Y75, RΖV ≥Y18 High risk groups"
GRC,Greece,EURO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"ZVL ≥Y60 -Y75, RΖV ≥Y18 High risk groups"
GRD,Grenada,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y4,4-5 Yr old
GRD,Grenada,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,M18 old
GRD,Grenada,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"high risk groups, health workers and sanitation workers"
GRD,Grenada,AMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Target-9-10 years girls/ Grades 4-6 Doses- 1 (1 dose commenced in 2023)
GRD,Grenada,AMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Target-9-10 years girls/ Grades 4-6 Doses- 1 (1 dose commenced in 2023)
GRD,Grenada,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
GRD,Grenada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y14-Y15,14yrs old
GRD,Grenada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Given to adults and pregnant women as needed based on vaccination history
GRD,Grenada,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Contacts to cases/ in outbreaks
GRD,Grenada,AMRO,2023.0,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Contacts to cases/ in outbreaks
GRD,Grenada,AMRO,2023.0,VARICELLA,Varicella vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Contacts to cases/ in outbreaks
GRD,Grenada,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y1,Travellers >1 yr of age going to endemic countries
GTM,Guatemala,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W4,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Personal de salud con mayor riesgo laboral, Personal de salud en contacto con secreciones corporales, Personal de salud con accidente laboral, Estudiantes de medicina, Estudiantes de odontología, Estudiante Químico-Biólogo/Técnico de alboratorio, Estudiante de enfermería, estudiante de Bachillerato en medicina, Personal que traslada pacientes a hospitales (cuerpo de socorro), Enfermos sometidos a hemodiálisis, Pacientes con trastornos hemorrágicos, Pacientes VIH positivo, Pacientes víctimas de violencia sexual a partir de los 18 años, otros grupos de riesgo (contacto con fluidos potencialmente infecciosos).  En año 2022-23 se priorizaron a las embarazadas con factores de riesgo para hepatitis."
GTM,Guatemala,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,"El AÑO 2023, fue un año de transición para cambiar el esquema de 2 dosis a esquema de 1 dosis (única)además se incrementó el grupo objetivo de esta vacunación para: Niñas de 9 a 16 años de edad, incluyendo a las niñas de 17 años cumplidos siempre y cuando hubieran nacido en el año 2006, Solamente se administró 2da. dosis a todas aquellas niñas que presentarán su carné de vacunación con cita para esa segunda dosis, pero que había sido escrita previamente al año 2023. En el 2018 se inició con 2 cohortes de niñas  en el año 2019 se incremento a 3 cohortes de niñas en el año 2020 se incremento a 5 cohortes de niñas Por lo que en el año 2023, el cambio de esquema permitió que la vacuna alcanzará iniciar a cubrir 9 cohortes niñas nacidas desde año 2006 hasta el año 2014"
GTM,Guatemala,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7-Y15,"Recuperación de esquema entre 7 a 15 años, si nunca a sido vacunada la persona"
GTM,Guatemala,AMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7-Y10,Recuperación de esquema entre 7 a 10 años
GTM,Guatemala,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Estudiantes de escuelas formadoras en salud previo práctica hospitalaria, personal del ministerio en accciones operativas de supervisión y/o monitoreo, personal del sector turístico y red hotelera, comadronas, brigadas de salud militar, población migrante, cuerpos de socorro y personal de medios/instituciones que realiza visitas a centros de salud."
GTM,Guatemala,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Enfermos crónicos de 2 años de edad en adelante, diciembre 2022 capacitaciones, , los datos adjuntos son de las dosis administradas durante todo el año 2023, se continuarán vacunando siempre"
GTM,Guatemala,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Enfermos crónicos de 2 años, a partir de 2 años de edad, diciembre 2022 capacitaciones, los datos adjuntos son de las dosis administradas durante todo el año 2023, se continuarán vacunando siempre"
GTM,Guatemala,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses despues de la 3ra. dosis SegundoRefuerzo; 6 meses despues del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Ademas Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis segun antecedente vacunal) por mordedura de perro   (cantidad de dosis segun antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses después de la 3ra. dosis, Segundo Refuerzo; 6 meses después del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Además  vacuna Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis según antecedente vacunal) por mordedura de perro   (cantidad de dosis según antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses después de la 3ra. dosis, Segundo Refuerzo; 6 meses después del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Además  vacuna Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis según antecedente vacunal) por mordedura de perro   (cantidad de dosis según antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Vacuna Td en niños mayores de 7 años como esquema atrasado, según dosis pendiente: pentavalente (3 dosis)o DPT(2 refuerzos), por lo cual: 1ra. Dosis en el primer contacto,  2da. Dosis  4 semanas después (1 mes)  3ra. Dosis 6 meses después de la segunda Primer Refuerzo; 6 meses después de la 3ra. dosis, Segundo Refuerzo; 6 meses después del  primer refuerzo Tercer refuerzo; a los 10 años de edad si tienen esquema completo con pentavalente (3 dosis ) y DPT (dos refuerzos).   Además  vacuna Td se administra como profilaxis antitetánica en: embarazadas (las dosis de Td se intercalan con la dosis vacuna Tdap durante el embarazo según semanas de gestación en el que sea captada y antecedente vacunal) por heridas contaminadas (cantidad de dosis según antecedente vacunal) por mordedura de perro   (cantidad de dosis según antecedente vacunal) de forma preventiva a personas que laboran en oficios que les puede genera riesgo a sufrir heridas (recolectores de basura, chatarreros etc)"
GTM,Guatemala,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,NATIONAL,1st contact,"Embarazadas (en cada embarazo), Personal de salud (dosis única)"
GTM,Guatemala,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,NATIONAL,1st contact,"Embarazadas (en cada embarazo), Personal de salud (dosis única)"
GTM,Guatemala,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M6-Y59,Viajeros entre 9 meses a 59 años que su destino son países endemicos o con brotes de FA
GUM,Guam,WPRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,Adults 19-64 Y
GUM,Guam,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y19,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y19,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,Td or Tdap booster every 10 yrs
GUM,Guam,WPRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y50,"and at 50 years, +M6 for high risk groups/adults"
GUM,Guam,WPRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"and at 50 years, +M6 for high risk groups/adults"
GUY,Guyana,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,SUBNATIONAL,+M6,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,SUBNATIONAL,1st contact,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,SUBNATIONAL,+M1,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M1,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"High risk groups, health care and allied workers"
GUY,Guyana,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y16,"Vaccine is given to both sexes 9-16 years, at 2 doses for 9-14 years and 3 doses for ages 15-16 years (at 15 years it is given at D0, M1 and M6)"
GUY,Guyana,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Vaccine is given to both sexes 9-16 years, at 2 doses for 9-14 years and 3 doses for ages 15-16 years (at 15 years it is given at D0, M1 and M6)"
GUY,Guyana,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,HIV exposed infants
GUY,Guyana,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,HIV exposed infants
GUY,Guyana,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,Vaccines given to Muslim clients for Hajj and special groups like sicklers
GUY,Guyana,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,"Risk groups, chronic disease clients, post op clients"
GUY,Guyana,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Risk groups, chronic disease clients, post op clients"
GUY,Guyana,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women depending on their primary series
GUY,Guyana,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,Pregnant women depending on their primary series
GUY,Guyana,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,ADULTS,Adults,SUBNATIONAL,Y18,"Risk groups; living in orphanages, and adults"
GUY,Guyana,AMRO,2023.0,VARICELLA,Varicella vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+M1,"Risk groups; living in orphanages, and adults"
GUY,Guyana,AMRO,2023.0,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M1,"Risk groups; living in orphanages, and adults"
GUY,Guyana,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Risk groups; living in orphanages, and adults"
HKG,"China, Hong Kong SAR",WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,female only
HKG,"China, Hong Kong SAR",WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11,female only
HKG,"China, Hong Kong SAR",WPRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Individuals with high risk conditions who have received 23vPPV or who have not received any pneumococcal vaccines before
HKG,"China, Hong Kong SAR",WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Individuals with high risk conditions who have received PCV13 or who have not received any pneumococcal vaccines before / Individuals without high risk conditions who have not received any pneumococcal vaccines before
HND,Honduras,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Población de 4 meses a 4 años alergicos al componente pertussis de Pentavalente
HND,Honduras,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Población de 4 meses a 4 años alergicos al componente pertussis de Pentavalente
HND,Honduras,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Población de 4 meses a 4 años alergicos al componente pertussis de Pentavalente
HND,Honduras,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Población de 4 meses a 4 años alergicos al componente pertussis de Pentavalente
HND,Honduras,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,1 Año
HND,Honduras,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,1 Año
HND,Honduras,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Tradbajadores de Salud
HND,Honduras,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,HW,Health workers,NATIONAL,+M6,Tradbajadores de Salud
HND,Honduras,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,4.0,HW,Health workers,NATIONAL,+Y1,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Grupos en riesgo: personal de salud, pacientes en dialisis, victimas de agresion sexual (21 días de la primera víctimas de agresión sexual), diversidad sexual, etc…"
HND,Honduras,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,Niñas de 11 y 12 años
HND,Honduras,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Niñas de 11 y 12 años
HND,Honduras,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Niños con madres con VIH y niños con diagnostico de VIH
HND,Honduras,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Niños con madres con VIH y niños con diagnostico de VIH
HND,Honduras,AMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y5,"Vacuna contra Sarampión, Rubéola y Parotiditis(Cepa Jeryl Lynn)  - Grupos en riesgo mayores de 5 años sin antecedente de haber padecido la enfermedad o de no haber sido vacunado."
HND,Honduras,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y11,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+M24,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+M36,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y10,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"11 años 1 refuerzo, Grupos en riesgo embarazadas no vacunadas completar esquema 5 dosis, otros grupos esquema de 3 dosis y un refuerzo a los 10 años"
HND,Honduras,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,HW,Health workers,SUBNATIONAL,1st contact,Embarazadas 26 a 37 SG y personal de salud durante brotes y a embarazadas en una región
HND,Honduras,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,PW,Pregnant women,SUBNATIONAL,1st contact,Embarazadas 26 a 37 SG y personal de salud durante brotes y a embarazadas en una región
HND,Honduras,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,Embarazadas 26 a 37 SG y personal de salud durante brotes y a embarazadas en una región
HND,Honduras,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y1,Viajeros de 1 año que viajan a zonas en riesgo de transmisión de Fiebre Amarilla
HRV,Croatia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y14,Females and males; in 8th grade of primary school
HRV,Croatia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6-M12,Females and males; in 8th grade of primary school
HTI,Haiti,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15,12-23 mois
HTI,Haiti,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
HTI,Haiti,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
HTI,Haiti,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
HTI,Haiti,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
HTI,Haiti,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
HUN,Hungary,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Boys and girls; 7th grade school campaign
HUN,Hungary,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Boys and girls; 7th grade school campaign
HUN,Hungary,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11,6th grade school campaign
IDN,Indonesia,SEARO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,DT will given to children Y7 equal specific target 1st grade in elementary school. Td 1st dose will given to children Y8 equal specific target 2nd grade in elementary school. Td 2nd dose will given to children Y10 equal specific target 5th grade in elementary school
IDN,Indonesia,SEARO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Surviving infants and Children under 2 years
IDN,Indonesia,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,"The nationwide introduction commenced in August 2023, 5th grade elementary school or 11 years of female in all provinces; meanwhile for the 2nd dose targeted 6th grade elementary school or 12 years of female for 132 districts"
IDN,Indonesia,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y12,"The nationwide introduction commenced in August 2023, 5th grade elementary school or 11 years of female in all provinces; meanwhile for the 2nd dose targeted 6th grade elementary school or 12 years of female for 132 districts"
IDN,Indonesia,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y15-Y39,Child-bearing women (15Y-39Y)
IDN,Indonesia,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y9-Y10,DT will given to children Y7 equal specific target 1st  grade in elementary school. Td 1st dose will given to children Y8 equal specific target 2nd grade in elementary school. Td 2nd dose will given to children Y10 equal specific target 5th grade in elementary school
IDN,Indonesia,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y7-Y8,DT will given to children Y7 equal specific target 1st  grade in elementary school. Td 1st dose will given to children Y8 equal specific target 2nd grade in elementary school. Td 2nd dose will given to children Y10 equal specific target 5th grade in elementary school
IND,India,SEARO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M16-M24,1.5 months-7 years
IND,India,SEARO,2023.0,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,1.5 months-7 years
IND,India,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y10,"10Y, 16Y, and 2 Td doses for pregnant women"
IND,India,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women 2nd dose of Td vaccine is administered after 4 weeks of 1st dose, at least 4 weeks before delivery"
IND,India,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,"Pregnant women 2nd dose of Td vaccine is administered after 4 weeks of 1st dose, at least 4 weeks before delivery"
IRL,Ireland,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M5,Healthcare workers
IRL,Ireland,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Healthcare workers
IRL,Ireland,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Healthcare workers
IRL,Ireland,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Risk groups
IRL,Ireland,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Risk groups
IRL,Ireland,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,Risk groups
IRL,Ireland,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Risk groups
IRL,Ireland,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Risk groups
IRL,Ireland,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M5,Risk groups
IRL,Ireland,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,"From 2019, switched to HPV9 and to females and males in first year of secondary school.  Since November 2022 a single dose of HPV vaccine is recommended in Ireland for those aged 9-24 years who are immunocompetent as there is now sufficient evidence that there is no significant difference in vaccine effectiveness between those aged nine to 24 years of age who are immunocompetent who receive one, two, or three vaccine doses."
IRL,Ireland,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,and child risk groups >2 years and adult risk groups
IRL,Ireland,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,Child risk groups >2 years and adult risk groups
IRN,Iran (Islamic Republic of),EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,M18,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",6.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M2,doses at 2 and 6 months for children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,doses at 2 and 6 months for children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,children with contraindication of pertussis vaccine
IRN,Iran (Islamic Republic of),EMRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,<Y25,"No specific target group, however this vaccine is distributed by the private sector"
IRN,Iran (Islamic Republic of),EMRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y25,"No specific target group, however this vaccine is distributed by the private sector"
IRN,Iran (Islamic Republic of),EMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y25,No specific target group however this vaccine is distributed by the private sector
IRN,Iran (Islamic Republic of),EMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,<Y25,No specific target group however this vaccine is distributed by the private sector
IRN,Iran (Islamic Republic of),EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y25,The booster dose of Td vaccine is recommended at 15 Y/O and repeated every 10 years later
IRN,Iran (Islamic Republic of),EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,The booster dose of Td vaccine is recommended at 15 Y/O and repeated every 10 years later
IRN,Iran (Islamic Republic of),EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y15,Recommended at 15 Y/O and repeated every 10 years later
IRQ,Iraq,EMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >60 years
ISL,Iceland,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Gender neutral and switch to HPV9 from birth cohort 2011
ISL,Iceland,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Gender neutral and switch to HPV9 from birth cohort 2011
ISR,Israel,EURO,2022.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,if pertussis contraindicated
ISR,Israel,EURO,2022.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,if pertussis contraindicated
ISR,Israel,EURO,2022.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,if pertussis contraindicated
ISR,Israel,EURO,2022.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,if pertussis contraindicated
ISR,Israel,EURO,2022.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y13,females and males
ISR,Israel,EURO,2022.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,females and males
ISR,Israel,EURO,2022.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65+
ISR,Israel,EURO,2022.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"M2, M4, M6, M12 for risk groups"
ISR,Israel,EURO,2022.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Wound management, +Y5 if the wound is deep"
ISR,Israel,EURO,2022.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,"Wound management, +Y5 if the wound is deep"
ISR,Israel,EURO,2022.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y13,Booster dose in school children
ISR,Israel,EURO,2022.0,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,Booster dose in school children
ISR,Israel,EURO,2022.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,>=Y60 all population + >=18 for risk group
ISR,Israel,EURO,2022.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,>=Y60 all population + >=18 for risk group
ITA,Italy,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,"females and males x2 doses, and MSM x3 doses"
ITA,Italy,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"females and males x2 doses, and MSM x3 doses"
ITA,Italy,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,1st contact,Every 10 years
ITA,Italy,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",3.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
ITA,Italy,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
JAM,Jamaica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4-Y6,Children <7Y with pertussis contraindication
JAM,Jamaica,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Children <7 yrs
JAM,Jamaica,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4-Y6,Children <7 yrs
JAM,Jamaica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,HCWs
JAM,Jamaica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W4,HCWs
JAM,Jamaica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,HCWs
JAM,Jamaica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Contacts of HepB positive cases
JAM,Jamaica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,Contacts of HepB positive cases
JAM,Jamaica,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Contacts of HepB positive cases
JAM,Jamaica,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children <1 year who are not eligible to receive the pentavalent vaccine with whole cell pertussis
JAM,Jamaica,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,"Females 9-26 years, Males 9-14 years (Main target is secondary school entry (grade 7) which is children Y11-12)"
JAM,Jamaica,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Females 9-26 years, Males 9-14 years (Main target is secondary school entry (grade 7) which is children Y11-12)"
JAM,Jamaica,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6
JAM,Jamaica,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6
JAM,Jamaica,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Persons who are immunocompromised receive the 2nd dose at +M1 and the 3rd dose at +M6
JAM,Jamaica,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Persons with Downs Syndrome and Sickle Cell Disease
JAM,Jamaica,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Persons with Downs Syndrome and Sickle Cell Disease
JAM,Jamaica,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Persons with Downs Syndrome and Sickle Cell Disease
JAM,Jamaica,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M15,Persons with Downs Syndrome and Sickle Cell Disease
JAM,Jamaica,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Persons with Sickle Cell Disease
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,Routine
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,RISKGROUPS,Risk group(s),NATIONAL,+Y10,"pregnant women and adults, 10 year booster given to risk groups"
JAM,Jamaica,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>M12,Travellers to endemic countries
JOR,Jordan,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Healthcare workers before clinical work
JOR,Jordan,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Healthcare workers before clinical work
JOR,Jordan,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Healthcare workers before clinical work
JOR,Jordan,EMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
JOR,Jordan,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
JOR,Jordan,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
JOR,Jordan,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
JOR,Jordan,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
JOR,Jordan,EMRO,2023.0,TT,TT (Tetanus toxoid) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
KAZ,Kazakhstan,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
KEN,Kenya,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y14,from October 2019; females
KEN,Kenya,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,from October 2019; females
KEN,Kenya,AFRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
KEN,Kenya,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
KEN,Kenya,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
KEN,Kenya,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
KEN,Kenya,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
KEN,Kenya,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
KGZ,Kyrgyzstan,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,11 лет
KGZ,Kyrgyzstan,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11,11 лет
KHM,Cambodia,WPRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,9y
KHM,Cambodia,WPRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M6,For responding to outbreaks temporarily
KHM,Cambodia,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
KHM,Cambodia,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
KHM,Cambodia,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
KHM,Cambodia,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
KHM,Cambodia,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
KIR,Kiribati,WPRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Female
KIR,Kiribati,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,15 years and above womens
KIR,Kiribati,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,15 years and above womens
KIR,Kiribati,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,15 years and above womens
KIR,Kiribati,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,15 years and above womens
KIR,Kiribati,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,15 years and above womens
KNA,Saint Kitts and Nevis,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,Given to boys and girls in grade 6 (Primary school) at 1st dose and 2nd dose six months later
KOR,Republic of Korea,WPRO,2023.0,HFRS,Hemorrhagic fever with renal syndrome vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,high risk groups
KOR,Republic of Korea,WPRO,2023.0,HFRS,Hemorrhagic fever with renal syndrome vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,high risk groups
KOR,Republic of Korea,WPRO,2023.0,HFRS,Hemorrhagic fever with renal syndrome vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M12,high risk groups
KOR,Republic of Korea,WPRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,females
KOR,Republic of Korea,WPRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,females
KOR,Republic of Korea,WPRO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"High risk groups (they are not managed by vaccination rate just check the number of vaccination, unknown denominator)"
KOR,Republic of Korea,WPRO,2023.0,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"High risk groups (they are not managed by vaccination rate just check the number of vaccination, unknown denominator)"
KOR,Republic of Korea,WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Adults and risk groups less than 65 years upon 1st contact and +5 months
KOR,Republic of Korea,WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Adults and risk groups less than 65 years upon 1st contact and +5 months
KOR,Republic of Korea,WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,Adults and risk groups less than 65 years upon 1st contact and +5 months
KOR,Republic of Korea,WPRO,2023.0,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,high risk groups only
KWT,Kuwait,EMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y9-Y45,Y9-Y45 males and females
KWT,Kuwait,EMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons at 65
LAO,Lao People's Democratic Republic,WPRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,from March 2020; females
LAO,Lao People's Democratic Republic,WPRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11-Y15,from March 2020; females
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LAO,Lao People's Democratic Republic,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"Pregnant women and Child Bearing Aged Women (up to 5 doses over lifetime), Health centres plan for up to 3 doses per pregnant women, but interval and frequency depends on previous Tetanus vaccination records."
LBR,Liberia,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,9-14 years Female
LBR,Liberia,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,9-14 years Female
LBR,Liberia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,15-49 Y
LBR,Liberia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+W4,15-49 Y
LBR,Liberia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,15-49 Y
LBR,Liberia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+M12,15-49 Y
LBR,Liberia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+M12,15-49 Y
LBY,Libya,EMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,females
LBY,Libya,EMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M2,females
LBY,Libya,EMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,FEMALE,HPV for females only,NATIONAL,+M4,females
LCA,Saint Lucia,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,from February 2019; females and males; in grade 6
LCA,Saint Lucia,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
LCA,Saint Lucia,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Infants with chronic diseases only
LCA,Saint Lucia,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Infants with chronic diseases only
LCA,Saint Lucia,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Infants with chronic diseases only
LCA,Saint Lucia,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y18,Older children with chronic diseases
LCA,Saint Lucia,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Based on request
LCA,Saint Lucia,AMRO,2023.0,VARICELLA,Varicella vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W6,Based on request
LCA,Saint Lucia,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Adult travellers
LKA,Sri Lanka,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y11,"10-11 year girls at schools in Grade 6 and field clinics if missed or if any drop outs, 2nd dose after 6 months"
LKA,Sri Lanka,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"10-11 year girls at schools in Grade 6 and field clinics if missed or if any drop outs, 2nd dose after 6 months"
LKA,Sri Lanka,SEARO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"x2 doses 6 weeks apart in 1st pregnancy, and x3 doses in subsequent pregnancies"
LSO,Lesotho,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5,Children from the age of 5 to 9 years
LSO,Lesotho,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y9,Children from the age of 5 to 9 years
LSO,Lesotho,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Expected pregnancies
LSO,Lesotho,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Expected pregnancies
LSO,Lesotho,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,Expected pregnancies
LSO,Lesotho,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Expected pregnancies
LSO,Lesotho,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Expected pregnancies
LTU,Lithuania,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,11 years (a minimum of 6 months betweeen first and second doses)
LTU,Lithuania,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,11 years (a minimum of 6 months betweeen first and second doses)
LTU,Lithuania,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,Males and females (from February 1)
LTU,Lithuania,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Males and females (from February 1)
LTU,Lithuania,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons >65 years
LTU,Lithuania,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y25,Every 10 years
LTU,Lithuania,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LTU,Lithuania,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years
LUX,Luxembourg,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y12,Catch-up vaccination against Hepatitis B if this vaccine has not yet been done
LUX,Luxembourg,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administered to babies born to a mother infected with hepatitis B
LUX,Luxembourg,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,Females and males
LUX,Luxembourg,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
LUX,Luxembourg,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"à partir de l’âge de 15 ans, chez les jeunes hommes et les jeunes femmes immunodéprimés et chez les hommes ayant des relations  sexuelles avec des hommes, par 3 doses de vaccin administrées à 0, 2 et 6  mois"
LUX,Luxembourg,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y15,"à partir de l’âge de 15 ans, chez les jeunes hommes et les jeunes femmes immunodéprimés et chez les hommes ayant des relations  sexuelles avec des hommes, par 3 doses de vaccin administrées à 0, 2 et 6  mois"
LUX,Luxembourg,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"à partir de l’âge de 15 ans, chez les jeunes hommes et les jeunes femmes immunodéprimés et chez les hommes ayant des relations  sexuelles avec des hommes, par 3 doses de vaccin administrées à 0, 2 et 6  mois"
LUX,Luxembourg,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,Older persons
LUX,Luxembourg,EURO,2023.0,MEN_B,Meningococcal B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M3-M12,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023.0,MEN_B,Meningococcal B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W8-M6,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023.0,MEN_B,Meningococcal B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"At risk groups of any age. 1st dose: 1) M12 / 2) M3-M11, 2nd dose: 1) +M6 for low or moderate risk / 2) +W8 for high risk, 3rd dose: M12-M23 with interval of +M6 between the 2nd and 3rd dose"
LUX,Luxembourg,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,enfants à risque (enfants nés prématurément)
LUX,Luxembourg,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3,enfants à risque (enfants nés prématurément)
LUX,Luxembourg,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M4,enfants à risque (enfants nés prématurément)
LUX,Luxembourg,EURO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,enfants à risque (enfants nés prématurément)
LUX,Luxembourg,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y65,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LUX,Luxembourg,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LUX,Luxembourg,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,PPV23 8 semaine après première dose de PCV13 pour age 65 et plus et groupes à risque. Booster tous les 5 ans avec PPV-23 uniquement pour les groupes à risques spécififques
LVA,Latvia,EURO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Infants who receive hepB mono vaccine due to hepB risk exposure from mothers
LVA,Latvia,EURO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Infants who receive hepB mono vaccine due to hepB risk exposure from mothers
LVA,Latvia,EURO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Infants who receive hepB mono vaccine due to hepB risk exposure from mothers
LVA,Latvia,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,For hemodialize patients (x3 doses)
LVA,Latvia,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Newborns with risk factors of hepB exposure from mothers (x4 doses)
LVA,Latvia,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Newborns with risk factors of hepB exposure from mothers (x4 doses)
LVA,Latvia,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Newborns with risk factors of hepB exposure from mothers (x4 doses)
LVA,Latvia,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12-M15,Newborns with risk factors of hepB exposure from mothers (x4 doses)
LVA,Latvia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
LVA,Latvia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
LVA,Latvia,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y17,Orphans and children left without parental care in the whole country
LVA,Latvia,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y17,Orphans and children left without parental care in the whole country
LVA,Latvia,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y17,Orphans and children left without parental care in the whole country
LVA,Latvia,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y1-Y17,Orphans and children left without parental care in the whole country
LVA,Latvia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Adult vaccination and revaccination
MAC,"China, Macao SAR",WPRO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018)  plus IPV for children at or above 7 years old during school grade 1 vaccination"
MAC,"China, Macao SAR",WPRO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y5-Y6,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018)  plus IPV for children at or above 7 years old during school grade 1 vaccination"
MAC,"China, Macao SAR",WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,"Non-immune individuals(>=Y18) and at high risk of Hepatitis B infection, esp. healthcare workers, sex partners or needle-sharing partners of people who have chronic hepatitis B infection, etc"
MAC,"China, Macao SAR",WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,Y15-Y17,"3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months."
MAC,"China, Macao SAR",WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10-Y14,"2-dose HPV for girls aged 10-14 years. 3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months."
MAC,"China, Macao SAR",WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"2-dose HPV for girls aged 10-14 years. 3-dose HPV for catch up girls aged 15-17 years. A 3-dose schedule is at 0, 2, 6 months."
MAC,"China, Macao SAR",WPRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >Y65
MAC,"China, Macao SAR",WPRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y18,Adults(>=Y18) born in or after 1970 who have neither been infected with measles nor received one dose of measles vaccine after their 1st birthday.  Non-immune health workers who have not received any measles vaccine after their 1st birthday. Full-time students enrolling in local higher education institutions for the first time who are not immune and have not received two doses of measles vaccine. Women of childbearing age(Y18 - Y50) with no immune of rubella.
MAC,"China, Macao SAR",WPRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,"Since September 2009, the 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been administered to chronic patients aged 2 or above and elderly individuals aged 60 or above. As of September 25, 2023, the protocol was adjusted to provide the 13-valent pneumococcal conjugate vaccine (PCV13) to chronic patients aged 2 or above and seniors aged 65 or above. They will be administered PCV13 first, followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) after one year. Individuals who have received the PPSV23 vaccine but not PCV13 are recommended to receive PCV13 one year after the PPSV23 vaccination."
MAC,"China, Macao SAR",WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y22,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y32,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y42,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y52,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y62,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,Y72,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018) plus IPV for children at or above 7 years old during school grade 1 vaccination. Tdap is used to replace Td for school grade 6 vaccination (11-12 years old) starting from September 2018. In some situations, when children have already competed 5th dose of IPV/OPV before school grade 1, we will then offer Tdap instead of Tdap-IPV for Tetanus booster."
MAC,"China, Macao SAR",WPRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11-Y12,"Regarding the 5th dose of DTP-IPV, DTP is replaced by Td (before September 2018) or Tdap (in and after September 2018) plus IPV for children at or above 7 years old during school grade 1 vaccination. Tdap is used to replace Td for school grade 6 vaccination (11-12 years old) starting from September 2018. In some situations, when children have already competed 5th dose of IPV/OPV before school grade 1, we will then offer Tdap instead of Tdap-IPV for Tetanus booster."
MAC,"China, Macao SAR",WPRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y7,Pregnant women in each pregnancy(between 27-36 weeks); adults(>=Y18) with no vaccination history of pertussis; adults and adolescents(>=Y7) with no vaccination history of DTP
MAC,"China, Macao SAR",WPRO,2023.0,TDAP_S_IPV,"Tdap-IPV (Tetanus, diphtheria for older children and adults, acellular pertussis and IPV) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y7,"Since 1 September 2020, all people are given administration of DTaP-IPV or Tdap-IPV."
MAC,"China, Macao SAR",WPRO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y22,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TT,TT (Tetanus toxoid) vaccine,2.0,ADULTS,Adults,NATIONAL,Y32,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TT,TT (Tetanus toxoid) vaccine,3.0,ADULTS,Adults,NATIONAL,Y42,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TT,TT (Tetanus toxoid) vaccine,4.0,ADULTS,Adults,NATIONAL,Y52,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TT,TT (Tetanus toxoid) vaccine,5.0,ADULTS,Adults,NATIONAL,Y62,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MAC,"China, Macao SAR",WPRO,2023.0,TT,TT (Tetanus toxoid) vaccine,6.0,ADULTS,Adults,NATIONAL,Y72,"According to vaccine supply, we use Td or TT as a 10-year booser dose of Tetanus"
MCO,Monaco,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y5,enfants de moins de 5 ans à risque de contracter une tuberculose
MCO,Monaco,EURO,2023.0,DTAPIPV,DTaP-IPV (acellular) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,"soit on administre le vaccin quadrivalent (exemple tetravac acellulaire https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66543281&typedoc=R ) c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio (DTCaP en français et DTaP-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et à 6 ans - soit, ce qui est recommandé et ce qui se fait en pratique : on administre le vaccin hexavalent (exemple infanrix hexa  https://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62966063# )  c’est-à-dire coqueluche acellulaire combiné avec diphtérie, tétanos et polio + Haemophilus influenzae b + hépatite b ( DTCaPHibHBV en français et DTaP-Hib-HepB-IPV en anglais) à 2 mois, 4 mois + rappel à 11 mois et on  fait un rappel à 6 ans avec le vaccin quadrivalent DTCaP"
MCO,Monaco,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Professionnal at risk, adults at risk"
MCO,Monaco,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M12,"Professionnal at risk, adults at risk"
MCO,Monaco,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health professionnels
MCO,Monaco,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Health professionnels
MCO,Monaco,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Health professionnels
MCO,Monaco,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Professionnal at risk (fireman, secourists)"
MCO,Monaco,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Professionnal at risk (fireman, secourists)"
MCO,Monaco,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Professionnal at risk (fireman, secourists)"
MCO,Monaco,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Babies born to a mother infected with hepatitis B
MCO,Monaco,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y14,"Femmes et hommes 11-14 ans; 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu'à l'âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d'autres hommes"
MCO,Monaco,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Femmes et hommes 11-14 ans; 2 doses (M0, +M6); Femmes et hommes 15-19 ans: 3 doses (M0, +M2, +M6), jusqu'à l'âge de 26 ans, chez les hommes ayant ou ayant eu des relations sexuelles avec d'autres hommes"
MCO,Monaco,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,and risk groups between 2-65 years
MCO,Monaco,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y65,and risk groups between 2-65 years
MDA,Republic of Moldova,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"При определении необходимости. Непривитые медработники, контактные из очагов острого и хронического вирусного гепатита В"
MDA,Republic of Moldova,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y10,девочкам. На территории Приднестровья вакцина не внеднена
MDA,Republic of Moldova,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,SUBNATIONAL,+M6,девочкам. На территории Приднестровья вакцина не внеднена
MDG,Madagascar,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1er contact grossesse - femmes enceintes
MDG,Madagascar,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1er contact grossesse - femmes enceintes
MDG,Madagascar,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1er contact grossesse - femmes enceintes
MDG,Madagascar,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes enceintes
MDG,Madagascar,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1er contact grossesse - femmes enceintes
MDV,Maldives,SEARO,2023.0,CHOLERA,Cholera vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y2,Travellers to endemic countries
MDV,Maldives,SEARO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y4,All children aged 4 years
MDV,Maldives,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,Females aged 10 years
MDV,Maldives,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females aged 10 years
MDV,Maldives,SEARO,2023.0,MEN_ACYW_135PS,Meningococcal ACYW polysaccharide vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>Y2,All travellers to Haj and Umrah and as per country travel requirements
MDV,Maldives,SEARO,2023.0,OPV,OPV (Oral polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,>M9,1. For pilgrims travelling to Haj and Umrah and 2. Travellers to Polio endemic countries
MDV,Maldives,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,>Y15 CBAW
MDV,Maldives,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,>Y15 CBAW
MDV,Maldives,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,>Y15 CBAW
MDV,Maldives,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,>Y15 CBAW
MDV,Maldives,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y2,>Y15 CBAW
MDV,Maldives,SEARO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>M9,All travellers to endemic countries
MEX,Mexico,AMRO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,< 5 años de edad.
MEX,Mexico,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,< 7 años de edad.
MEX,Mexico,AMRO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y1,Niños de 1 año de edad inscritos en guarderias o estancias infantiles
MEX,Mexico,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,> de 20 años sin antecedente vacunal. La vacuna unicamente se coloca al personal de salud que no tenga esquema completo o no tenga antecedente vacunal
MEX,Mexico,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y20,> de 20 años sin antecedente vacunal. La vacuna unicamente se coloca al personal de salud que no tenga esquema completo o no tenga antecedente vacunal
MEX,Mexico,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y13,"Para la campaña de recuperación de coberturas 2023 se consideró como población blanco a: Niñas y/o adolescentes de quinto año de primaria o de 11 años no escolarizadas. Niñas y/o adolescentes de sexto año de primaria o de 12 años no escolarizadas, Niñas y/o adolescentes de 1 de secundaria o de 13 años no escolarizadas."
MEX,Mexico,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,Mujeres CIS y TRANSGÉNERO de 11 a 49 años que viven con VIH
MEX,Mexico,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Mujeres CIS y TRANSGÉNERO de 11 a 49 años que viven con VIH
MEX,Mexico,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y11-Y49,Mujeres CIS y TRANSGÉNERO de 11 a 49 años que viven con VIH
MEX,Mexico,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y10,"10 años y más sin antecedente vacunal (Se administra de forma general a toda la población mayor de 10 años sin antecedente vacunal, lo cual incluye al personal de salud)."
MEX,Mexico,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60,Personas de 60 y más años sin factores de riesgo recibirán dosis única con esta vacuna. Personas de 60 y más años con factores de riesgo recibirán una dosis con esta vacuna y al año de aplicación recibirán una dosis de refuerzo con vacuna Neumocócica polisacárida 23 valente
MEX,Mexico,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y61,Personas de 61 años y más con factores de riesgo (12 meses después de haber recibido la vacuna antineumocócica conugada)
MEX,Mexico,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,"En población con  esquema primario completo, se vacuna con Td a población de primer año de educación secundaria y de 15 años no escolarizados , con refuerzo cada 10 años"
MEX,Mexico,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,>=Y15,"En población con  esquema primario completo, se vacuna con Td a población de primer año de educación secundaria y de 15 años no escolarizados , con refuerzo cada 10 años"
MEX,Mexico,AMRO,2023.0,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,Y1,Niños inscritos en estancias infantiles
MHL,Marshall Islands,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,females
MKD,North Macedonia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,Females only
MKD,North Macedonia,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females only
MKD,North Macedonia,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons >65 years
MKD,North Macedonia,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y18,"This is the last (7th dose) of Tetanus toxoid vaccine, according to Immunization Schedule for all children from 0-18 years of age"
MLI,Mali,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse - femmes enceintes
MLI,Mali,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse - femmes enceintes
MLT,Malta,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Babies of parents hailing from high-risk TB countriess
MLT,Malta,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Birth dose only to children born to HepB and/or HepC positive parents
MLT,Malta,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,W4,Birth dose only to children born to HepB and/or HepC positive parents
MLT,Malta,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,W8,Birth dose only to children born to HepB and/or HepC positive parents
MLT,Malta,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Birth dose only to children born to HepB and/or HepC positive parents
MLT,Malta,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y13-Y14,"As July 2023, we started a catch up campaign vaccinating all boys aged 13-14. These children wouldneed only 2 doses 6 months apart. a concomittant opportunistic campaign vaccinating boys 15 to 23 (boys born as of the year 2000 and being 12 years and over) when they present for other vaccines like travel vaccines or the DTP and Men ACWY vaccines."
MLT,Malta,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
MLT,Malta,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
MMR,Myanmar,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,9-10 years old girls
MMR,Myanmar,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women, 1st AN visit, and 4 weeks after first AN visit"
MMR,Myanmar,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Pregnant women, 1st AN visit, and 4 weeks after first AN visit"
MNE,Montenegro,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y6,"For children who attended first grade during the 2022/2023 school year and for older children who missed this revaccination, revaccination was carried out with the DT vaccine in 2023"
MNE,Montenegro,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,occasional birth dose for babies born by HBsAg+ mothers
MNE,Montenegro,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,W5,"for children with a contraindication to DTaP, IPV and/or Hib vaccine components."
MNE,Montenegro,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,W9,"for children with a contraindication to DTaP, IPV and/or Hib vaccine components."
MNE,Montenegro,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M13,"for children with a contraindication to DTaP, IPV and/or Hib vaccine components."
MNE,Montenegro,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,"HPV vaccination program in Montenegro started September, 26th 2022 in the primary group of girls of 9 y.o. (birth cohort 2013). Since March, 1st 2023 we started vaccination in all girls 9-14 y.o. and we decided to switch to one dose schedule (one dose for 9-20 y.o; two doses for 21-26 y.o; two doses for immunosuppressed people)."
MNE,Montenegro,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65+
MNP,Northern Mariana Islands,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"Both Male and Females are offered HPV  at age 9-14 years old for the first dose. The 2nd and 3rd dose depends on when the 1st dose was administered, but usually after 6 months. Age 15 and older is offered to both males and females. The recommended 3 dose schedule is 0, 1-2 and 6 months."
MNP,Northern Mariana Islands,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Both Male and Females are offered HPV  at age 9-14 years old for the first dose. The 2nd and 3rd dose depends on when the 1st dose was administered, but usually after 6 months. Age 15 and older is offered to both males and females. The recommended 3 dose schedule is 0, 1-2 and 6 months."
MNP,Northern Mariana Islands,WPRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
MOZ,Mozambique,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females 9
MOZ,Mozambique,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females 9
MOZ,Mozambique,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,females (15-49 years)
MOZ,Mozambique,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y49,females (15-49 years)
MOZ,Mozambique,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,females (15-49 years)
MOZ,Mozambique,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,females (15-49 years)
MOZ,Mozambique,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,females (15-49 years)
MOZ,Mozambique,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y6,school age
MOZ,Mozambique,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_F,General/routine,NATIONAL,Y7,school age
MRT,Mauritania,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,fils âgé de 9 ans
MRT,Mauritania,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,fils âgé de 9 ans
MRT,Mauritania,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
MRT,Mauritania,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
MRT,Mauritania,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
MRT,Mauritania,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
MRT,Mauritania,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
MSR,Montserrat,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y4.5,Y4 1/2 -5
MSR,Montserrat,AMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y13,females
MSR,Montserrat,AMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,SUBNATIONAL,+M6,females
MUS,Mauritius,AFRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,females aged 9 years old
MUS,Mauritius,AFRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,females aged 9 years old
MUS,Mauritius,AFRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y11,Primary school leavers
MWI,Malawi,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,from January 2019; females
MWI,Malawi,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+Y1,from January 2019; females
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"pregnant women, CBAW"
MWI,Malawi,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"pregnant women, CBAW"
MYS,Malaysia,WPRO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,From November 2020 onwards
MYS,Malaysia,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,HCWs
MYS,Malaysia,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,HCWs
MYS,Malaysia,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,HCWs
MYS,Malaysia,WPRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,Given to female students only as part of School Health programme
MYS,Malaysia,WPRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,"and older persons >=60 years (recommended but not as part of the national immunization programme, purchase on own from private sectors)"
MYS,Malaysia,WPRO,2023.0,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
MYS,Malaysia,WPRO,2023.0,TYPHOID_PS,Typhoid polysaccharide vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y3,All food handlers as required by Malaysian Food Hygiene Regulation - given every 3 years
NAM,Namibia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y15-Y49,CBAW
NAM,Namibia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,CBAW
NAM,Namibia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,CBAW
NAM,Namibia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,CBAW
NAM,Namibia,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,CBAW
NCL,New Caledonia,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y14,"filles et rattrapage pour les filles de 14 ans; Elargissement aux garçons à partir de novembre 2022, et avancement de l'âge à 9 ans. Cependant, les campagnes scolairee de vaccination se font à l'âge de 11 ans."
NCL,New Caledonia,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"filles et rattrapage pour les filles de 14 ans; Elargissement aux garçons à partir de novembre 2022, et avancement de l'âge à 9 ans. Cependant, les campagnes scolairee de vaccination se font à l'âge de 11 ans."
NCL,New Caledonia,WPRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons >=65 years
NER,Niger,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes de 15-49 ans
NER,Niger,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes de 15-49 ans
NGA,Nigeria,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y9,9 years
NGA,Nigeria,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
NGA,Nigeria,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
NGA,Nigeria,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
NGA,Nigeria,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
NGA,Nigeria,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
NIC,Nicaragua,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Grupo de 18 meses y el de 6 años
NIC,Nicaragua,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y6,Grupo de 18 meses y el de 6 años
NIC,Nicaragua,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Grupos de Riesgo, principalmente trabajadores de la salud del sector público y privado, algunos pacientes con Insuficiencia Renal Crónica. El  esquema es de tres dosis: 1ra dosis/Primer contacto  - 2da dosis/1 mes después - 3ra dosis/6 meses (5 meses despúes de la 1era dosis)"
NIC,Nicaragua,AMRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,"10 años sexo femenino. Durante el primer año de introducción también se vacuna con dos dosis a niñas de 11,12,13 y 14 años"
NIC,Nicaragua,AMRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"10 años sexo femenino. Durante el primer año de introducción también se vacuna con dos dosis a niñas de 11,12,13 y 14 años"
NIC,Nicaragua,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y13,"Grupos de Riesgo: trabajadores de la salud, adultos y trabajadores de embarcaciones, sin documentación de su historia y es un requisito, se le aplica esta vacuna. Vacunacion adultos en un brote."
NIC,Nicaragua,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y50,Cohorte de 50 años y algunos pacientes adultos con esplenectomia
NIC,Nicaragua,AMRO,2023.0,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Grupo de riesgo que sufre lesiones por aniimales transmisores de rabia, se aplica en todas edades lo que varía es la dosis, esta se calcula según peso del lesionado.."
NIC,Nicaragua,AMRO,2023.0,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,"Grupo de riesgo que sufre lesiones por aniimales transmisores de rabia, se aplica en todas edades lo que varía es la dosis, esta se calcula según peso del lesionado.."
NIC,Nicaragua,AMRO,2023.0,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,"Grupo de riesgo que sufre lesiones por aniimales transmisores de rabia, se aplica en todas edades lo que varía es la dosis, esta se calcula según peso del lesionado.."
NIC,Nicaragua,AMRO,2023.0,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,"Grupo de riesgo que sufre lesiones por aniimales transmisores de rabia, se aplica en todas edades lo que varía es la dosis, esta se calcula según peso del lesionado.."
NIC,Nicaragua,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y20,Grupo de 10 y 20 años
NIC,Nicaragua,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,Grupo de 10 y 20 años
NIC,Nicaragua,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Embarazadas - 1 dosis en el primer embarazo
NIC,Nicaragua,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"20 años; Población mayor de 20 años que no cuentan con historial de haber recibido las dosis primarias se aplica un esquema de 5 dosis: 1ra al contacto, 2da a los 4 meses de la 1era, 3era a los 6 meses de la 2da,, 4ta al año de la 3era dosis y una 5ta al año de la 4ta dosis; Embarazadas - 1 dosis en el primer embarazo"
NIC,Nicaragua,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9-Y59,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIC,Nicaragua,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M9-Y59,Grupos de Riesgo/Viajeros desde los 9 meses hasta 59 años. Una sola dosis.
NIU,Niue,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,females and males; x2 doses administered to all persons <=14 years (2nd dose administered +6 months after the 1st dose)
NIU,Niue,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,females and males; x2 doses administered to all persons <=14 years (2nd dose administered +6 months after the 1st dose)
NLD,Netherlands (Kingdom of the),EURO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Additional vaccination at M2 when mother is not vaccinated against pertussis during pregnancy and in some other special situaions
NLD,Netherlands (Kingdom of the),EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<D2,<H48; children of carrier mothers
NLD,Netherlands (Kingdom of the),EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10,Females and males
NLD,Netherlands (Kingdom of the),EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
NOR,Norway,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Defined risk groups
NOR,Norway,EURO,2023.0,DTAPHIBHEPBIPV,DTaP-Hib-HepB-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6,Defined risk groups (premature born)
NOR,Norway,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Defined risk groups
NOR,Norway,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Defined risk groups
NOR,Norway,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M3,Defined risk groups
NOR,Norway,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M5,Defined risk groups
NOR,Norway,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,M12,Defined risk groups
NOR,Norway,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females and males
NOR,Norway,EURO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
NPL,Nepal,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Pregnant women; at first visit during first pregnancy, 1 month interval after first dose, 1 dose each in subsequent pregnancy"
NPL,Nepal,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Pregnant women; at first visit during first pregnancy, 1 month interval after first dose, 1 dose each in subsequent pregnancy"
NZL,New Zealand,WPRO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,At-risk neonates
NZL,New Zealand,WPRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,infants born to mothers who are HBs-AG-positive; and other risk groups and children <18 years who require vaccination to achieve positive serology or to complete primary series of vaccination
NZL,New Zealand,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y13,"females and males; x2 doses in school years 7 and 8, 3rd dose if started from Y15+. HPV immunisation is also funded in general practice for anyone aged 9 to 26 years"
NZL,New Zealand,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y13,"females and males; x2 doses in school years 7 and 8, 3rd dose if started from Y15+. HPV immunisation is also funded in general practice for anyone aged 9 to 26 years"
NZL,New Zealand,WPRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y65,"Y45 dose if for persons who have not had 4 previous tetanus vaccines, Y65 for all adults, and for pregnancy between 28 and 38 weeks' gestation"
NZL,New Zealand,WPRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y45,"Y45 dose if for persons who have not had 4 previous tetanus vaccines, Y65 for all adults, and for pregnancy between 28 and 38 weeks' gestation"
NZL,New Zealand,WPRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y65,"in December 2022, NZ changed from a one-dose live varicella-zoster virus vaccine, to a two-dose adjuvanted recombinant subunit zoster vaccine"
NZL,New Zealand,WPRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y65,"in December 2022, NZ changed from a one-dose live varicella-zoster virus vaccine, to a two-dose adjuvanted recombinant subunit zoster vaccine"
OMN,Oman,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6,school students at grade 1
OMN,Oman,EMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",3.0,ADULTS,Adults,NATIONAL,>Y34,post partum
PAK,Pakistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
PAK,Pakistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
PAK,Pakistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
PAK,Pakistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
PAK,Pakistan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
PAN,Panama,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,NATIONAL,>=Y19,">  19 AÑOS,MANIPULADORES DE ALIMENTOS, FUNC. DE SALUD.RECOLECTORES DE BASURA Y DESECHOS PELIGROSOS."
PAN,Panama,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y19,">  19 AÑOS,MANIPULADORES DE ALIMENTOS, FUNC. DE SALUD.RECOLECTORES DE BASURA Y DESECHOS PELIGROSOS."
PAN,Panama,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"MANIPULADORES DE ALIMENTOS, FUNC, DE SALUD, TRABAJADORAS DEL SEXO COMERCIAL"
PAN,Panama,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"NIÑOS Y NIÑAS DE 10 AÑOS ADEMAS VICTIMAS DE VIOLACION SEXUAL A PARTIR DE LOS 10 AÑOS, PACIENTES VIH RECLUIDOS EN CLINICA RETRO VIRALES"
PAN,Panama,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10,"NIÑOS Y NIÑAS DE 10 AÑOS ADEMAS VICTIMAS DE VIOLACION SEXUAL A PARTIR DE LOS 10 AÑOS, PACIENTES VIH RECLUIDOS EN CLINICA RETRO VIRALES"
PAN,Panama,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >Y60
PAN,Panama,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,PACIENTES INMUNOSUPRIMIDOS
PAN,Panama,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,PACIENTES INMUNOSUPRIMIDOS
PAN,Panama,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y19,"MAYORES DE 19 AÑOS, PUERPERAS, MEF"
PAN,Panama,AMRO,2023.0,MR,MR (Measles and rubella) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>Y19,"MAYORES DE 19 AÑOS, PUERPERAS, MEF"
PAN,Panama,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,"2 DOSIS Y 1 REFUERZO A  NIÑOS, < 2 AÑOS, 1 DOSIS A > 60 AÑOS, 1 DOSIS A PTES CON ENF CRONICA INDEPENDIENTE LA EDAD."
PAN,Panama,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60,"ADICIONAL PACIENTES CON ENF, CRONICA INDEPENDIENTE DE LA EDAD."
PAN,Panama,AMRO,2023.0,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Pre Exposición
PAN,Panama,AMRO,2023.0,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,Pre Exposición
PAN,Panama,AMRO,2023.0,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,Pre Exposición
PAN,Panama,AMRO,2023.0,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,Pre Exposición
PAN,Panama,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,NIÑOS A PARTIR DE LOS 6 AÑOS Y ADULTOS ETC DOS DOSIS Y UN REF
PAN,Panama,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y10,niños y niñas 10 años
PAN,Panama,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y4-Y64,"Emb, pareja, cuidadores, Adultos Mayores, puerperas, pob de 4 a 64 años en el perifoco de casos sospechosos de tosferina."
PER,Peru,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M4,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M6,aplicado cuando se tiene reaccion adversa a la vacuna pentavalente
PER,Peru,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,Y5,Población que no recibio el esquema primario
PER,Peru,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,Población que no recibio el esquema primario
PER,Peru,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,Población que no recibio el esquema primario
PER,Peru,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M4,in case of contradiction to pentavalent vaccine
PER,Peru,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M6,in case of contradiction to pentavalent vaccine
PER,Peru,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9,"Se aplica dosis UNICA en el 5to grado de primaria, aplicada a mujeres y varones"
PER,Peru,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,Adultos mayores de 60 años a más
PER,Peru,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M2,+M2 y +M6 dosis: Son dosis de recuperación aplicados a la población que no recibió esquema primario
PER,Peru,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,+M2 y +M6 dosis: Son dosis de recuperación aplicados a la población que no recibió esquema primario
PHL,Philippines,WPRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y9-Y14,females; grade 4
PHL,Philippines,WPRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,SUBNATIONAL,+M6,females; grade 4
PHL,Philippines,WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y60,Indigent elderly
PHL,Philippines,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,all pregnant women in 1st trimester
PHL,Philippines,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,all pregnant women in 1st trimester
PLW,Palau,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,1st contact,Females upon 1st contact
PLW,Palau,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females upon 1st contact
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,B_ADO_W,General/routine,NATIONAL,Y13,"Y7 dose is school vaccination entry, Y13 is school vaccination at exit"
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,B_CHILD_W,General/routine,NATIONAL,Y7,"Y7 dose is school vaccination entry, Y13 is school vaccination at exit"
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Both adults and pregnant women
PNG,Papua New Guinea,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Both adults and pregnant women
POL,Poland,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,W7-W8,For those who cannot be given pertusis vaccine
POL,Poland,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M3-M4,For those who cannot be given pertusis vaccine
POL,Poland,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M5-M6,For those who cannot be given pertusis vaccine
POL,Poland,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M16-M18,For those who cannot be given pertusis vaccine
POL,Poland,EURO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W7-W8,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M3-M4,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M5-M6,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M16-M18,Risk groups who cannot be given whole-cell pertusus
POL,Poland,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >75 years
POL,Poland,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y19,Routinely at Y19 and free of charge (mandatory) post-exposure prophylaxis at a later age
POL,Poland,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,1st and 2nd booster doses
POL,Poland,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,B_ADO_W,General/routine,NATIONAL,Y14,1st and 2nd booster doses
POL,Poland,EURO,2023.0,VARICELLA,Varicella vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y12,Specified risk groups
PRT,Portugal,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,D0-Y5,Specific risk group
PRT,Portugal,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10,Females and males
PRT,Portugal,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,Females and males
PRT,Portugal,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Specific risk groups (pre and post-exposure)
PRT,Portugal,EURO,2023.0,MPOX,Mpox (monkeypox) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,D28,Specific risk groups (pre and post-exposure)
PRT,Portugal,EURO,2023.0,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Specific risk groups
PRT,Portugal,EURO,2023.0,ROTAVIRUS_1,RV-1 (Rotavirus 1-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Specific risk groups
PRT,Portugal,EURO,2023.0,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Specific risk groups
PRT,Portugal,EURO,2023.0,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Specific risk groups
PRT,Portugal,EURO,2023.0,ROTAVIRUS_5,RV-5 (Rotavirus 5-valent) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Specific risk groups
PRT,Portugal,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25,Adults
PRT,Portugal,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y45,Adults
PRT,Portugal,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y65,Adults
PRT,Portugal,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Adults
PRT,Portugal,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Adults
PRY,Paraguay,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Esta vacuna se utiliza en niños con contra indicaciones de aplicarse la DPT a células enteras.
PRY,Paraguay,AMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"En inmuno comprometidos, Enfermos hepáticos crónico."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M1,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+M6,"Trabajadores de la salud, adolescentes con conductas de riesgo, homosexuales o bisexuales con más de una pareja, adictos a drogas endovenosas, heterosexuales con más de una pareja o antecedentes de enfermedades de transmisión sexual, convivientes y contactos sexuales con portadores del virus de hepatitis b o personas con infección aguda, hemodializados y pacientes con insuficiencia renal, personal y pacientes de instituciones con discapacitados mentales, pacientes que deben recibir transfusiones frecuentes, pacientes HIV, hepatopatías crónicas de otra etiología diferente de hepatits b, pacientes en lista para transplante de órganos, prisioneros o personal de cárceles, viajeros a países de alta endemicidad y pacientes que reciben factores de coagulación en forma periódica."
PRY,Paraguay,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"a) niños menores de 5 años que requieran realizarse una esplenoctomía programada con esquema primario completo y dosis de refuerzo, podrán beneficiarse con una dosis adicional de vacuna conjugada contra Hib administrada 7-10 días antes del procedimiento, b) infección por VIH, c) deficít de inmunoglobulina subclase 2 (IgG2), d) oncológicos, e) trasplantados con precursores hematopoyéticos y f) trasplante de órgano sólido g) niños entre 12 - 59 meses con afección subyacente que no fueron inmunizados o sólo hayan recibido una única dosis antes de los 12 meses de edad, deben recibir dos dosis de vacuna anti - haemophilus influenzae b (con intervalos de 2 meses entre dosis) y en caso de haber recibido dos dosis antes de los 12 meses de vida se recomienda administrar una dosis adicional."
PRY,Paraguay,AMRO,2023.0,HIB,Hib (Haemophilus influenzae type B) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"a) niños menores de 5 años que requieran realizarse una esplenoctomía programada con esquema primario completo y dosis de refuerzo, podrán beneficiarse con una dosis adicional de vacuna conjugada contra Hib administrada 7-10 días antes del procedimiento, b) infección por VIH, c) deficít de inmunoglobulina subclase 2 (IgG2), d) oncológicos, e) trasplantados con precursores hematopoyéticos y f) trasplante de órgano sólido g) niños entre 12 - 59 meses con afección subyacente que no fueron inmunizados o sólo hayan recibido una única dosis antes de los 12 meses de edad, deben recibir dos dosis de vacuna anti - haemophilus influenzae b (con intervalos de 2 meses entre dosis) y en caso de haber recibido dos dosis antes de los 12 meses de vida se recomienda administrar una dosis adicional."
PRY,Paraguay,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y14,Niñas de 9 a 14 años de edad.
PRY,Paraguay,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Niñas de 9 a 14 años de edad.
PRY,Paraguay,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=60 years
PRY,Paraguay,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adicionalmente se administra a grupos de alto riesgo, pacientes con inmunocompromiso. Las personas inmunodeprimidas, por las mismas características de la inmunodefensa, no deben recibir vacunas compuestos por agentes vivos atenuados. De tal manera a que una de las indicaciones es recibir vacunas inactivadas como es el caso de la vacuna frente al Polio Virus Antipoliomielitica Inactivada (IPV). Indicada además en Pacientes que padecen alguna inmunodeficiencia primaria o secundaria, al igual que sus contactos cercanos, por el riesgo de parálisis asociada a la vacuna OPV. Mayores de 18 años que requieren completar esquemas o reforzarlos ante situaciones de riesgo (viajeros, epidemias)."
PRY,Paraguay,AMRO,2023.0,IPV,IPV (Inactivated polio vaccine),1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Adicionalmente se administra a grupos de alto riesgo, pacientes con inmunocompromiso. Las personas inmunodeprimidas, por las mismas características de la inmunodefensa, no deben recibir vacunas compuestos por agentes vivos atenuados. De tal manera a que una de las indicaciones es recibir vacunas inactivadas como es el caso de la vacuna frente al Polio Virus Antipoliomielitica Inactivada (IPV). Indicada además en Pacientes que padecen alguna inmunodeficiencia primaria o secundaria, al igual que sus contactos cercanos, por el riesgo de parálisis asociada a la vacuna OPV. Mayores de 18 años que requieren completar esquemas o reforzarlos ante situaciones de riesgo (viajeros, epidemias)."
PRY,Paraguay,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,"En situaciones y poblaciones especiales. a) Personas de 2 a 55 años con asplenia anatómica o funcional, o déficit de factores terminales del complemento, deben recibir 1 dosis y un refuerzo cada 5 años. b) Personal de salud o trabajadores de laboratorio de microbiología que manipulan o procesan cultivos bacteriológicos con potencial exposición a Neisseria meningitidis: una sola dosis con revacunación cada 5 años mientras se mantenga la exposición. c) Niños con infección por VIH."
PRY,Paraguay,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"En situaciones y poblaciones especiales. a) Personas de 2 a 55 años con asplenia anatómica o funcional, o déficit de factores terminales del complemento, deben recibir 1 dosis y un refuerzo cada 5 años. b) Personal de salud o trabajadores de laboratorio de microbiología que manipulan o procesan cultivos bacteriológicos con potencial exposición a Neisseria meningitidis: una sola dosis con revacunación cada 5 años mientras se mantenga la exposición. c) Niños con infección por VIH."
PRY,Paraguay,AMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Para la inmunización activa contra el sarampión y rubéola en bebés, niños, adolescentes y adultos jóvenes en riesgo. A partir de los 11 años de edad podrá ser administrada la vacuna triple viral en aquellas personas que no cuenten con antecedente de vacunación previa con 2 dosis de SPR, debido a que la vacuna Triple viral forma parte del esquema de vacunación nacional en edades de 12 y 18 meses."
PRY,Paraguay,AMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Para la inmunización activa contra el sarampión y rubéola en bebés, niños, adolescentes y adultos jóvenes en riesgo. A partir de los 11 años de edad podrá ser administrada la vacuna triple viral en aquellas personas que no cuenten con antecedente de vacunación previa con 2 dosis de SPR, debido a que la vacuna Triple viral forma parte del esquema de vacunación nacional en edades de 12 y 18 meses."
PRY,Paraguay,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y60,"La vacuna neumococica polisacarida 23 valente se administra a toda persona de igual o mayor edad a 60 años, adicionalmente a personas de alto riesgo de padecer enfermedad invasiva por Streptococcus pneumoniae. La vacuna 23 valente está indicada para los niños a partir de los dos años de edad y en adultos que integran los grupos de alto riesgo de padecer enfermedad invasiva por Streptococcus pneumoniae, dictados a continuación: anemia drepanocítica, cardiopatia congénita, enfermedades pulmonares crónicas, diabetes mellitus, hepatopatía crónica, fistula de LCR, asplenia funcional o anatómica, implante coclear, 60 años o mayor, infección por VIH, leucemias, neoplasias, falla renal crónica, sindrome nefrótico, tabaquismo."
PRY,Paraguay,AMRO,2023.0,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023.0,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023.0,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023.0,RABIES,Rabies vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+D7,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023.0,RABIES,Rabies vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023.0,RABIES,Rabies vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+Y1,"Pre exposición: constituye un grupo de personas que no fueron mordidos por ningún tipo de animal, pero debido al tipo de exposición se considera de alto riesgo: Veterinarios, Biólogos, Laboratoristas, Personal de Zoológico, Personas que viajan a países endémicos de rabia. Consiste en la aplicación de 2 (dos) dosis primarias no mas a 2,5UI por dosis, la 1ra(día 0) y 2da(7 días) y un refuerzo al año. Post Exposición: En función de la gravedad del contacto con el animal presuntamente rabioso 1ra dosis en día ""0"", 2da dosis en día ""3"", 3ra dosis en día ""7"" y 4ta dosis en día ""14"". Se administran a quienes han mantenido contacto con mordeduras o arañazos transdermicos (uno o más), lamedura en piel lesionada; contaminación de mucosas con saliva por lamedura; contacto con murciélagos, animales silvestres. Se administra la inmunoglobulina en un máximo de 7 (siete) días posterior al inicio del tratamiento coincidentemente con la tercera dosis de la vacuna antirrábica de uso humano."
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,CATCHUP_A,Catch-up adults,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_A,Catch-up adults,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,CATCHUP_A,Catch-up adults,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,1st contact,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_A,Catch-up adults,NATIONAL,+M1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,>=Y7,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,CATCHUP_C,Catch-up children,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,CATCHUP_C,Catch-up children,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+Y1,Se administra como puesta al día en adultos y niños a partir de los 7 años de edad de acuerdo al antecedente de vacunación.
PRY,Paraguay,AMRO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Adicionalmente al Personal de salud dosis única, Embarazadas a partir de las 20 semanas de gestación en cada embarazo, Puérperas que no lo han recibido durante su embarazo con hijos menores de 6 meses."
PRY,Paraguay,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y2-Y59,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PRY,Paraguay,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,Y2-Y59,"Dentro del calendario regular a los 1 años de edad, adicionalmente también podrá administrarse a la población de 2 a 59 años que aún no hayan recibido la vacuna y se desplacen a paises endémicos."
PSE,"occupied Palestinian territory, including east Jerusalem",EMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
PYF,French Polynesia,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Healthcare workers
PYF,French Polynesia,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Healthcare workers
PYF,French Polynesia,WPRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Healthcare workers
PYF,French Polynesia,WPRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Preterm or risk of invasive pneumococcal infection (chronic disease)
PYF,French Polynesia,WPRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,Prime boost scheme: 1st dose with PCV13 and 2nd dose with PPV
QAT,Qatar,EMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,Two doses 6 months apart are recommended for those with frequent travel to high risk countries
QAT,Qatar,EMRO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+M6,Two doses 6 months apart are recommended for those with frequent travel to high risk countries
QAT,Qatar,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M2,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M2,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"3 doses are recommended at 0, 2, 6 months apart especially for those with high risk of exposure like the health care workers and laboratory personal"
QAT,Qatar,EMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y14,"Males and females aged 11-26 years: 9-14 years x2 doses of 0.5ml at 0, 6 months; 15 years and above x3 doses of 0.5ml at 0, 1 and 6 months"
QAT,Qatar,EMRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Males and females aged 11-26 years: 9-14 years x2 doses of 0.5ml at 0, 6 months; 15 years and above x3 doses of 0.5ml at 0, 1 and 6 months"
QAT,Qatar,EMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >65 years
QAT,Qatar,EMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,travellers and high risk
QAT,Qatar,EMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y2,travellers and high risk
QAT,Qatar,EMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y2,high risk groups
ROU,Romania,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y18,11-18 y girls on request
ROU,Romania,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >65 years old
RUS,Russian Federation,EURO,2023.0,ANTHRAX,Anthrax vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Специфическая профилактика сибирской язвы  проводится  с 14-летнего возраста. Вакцинацию проводят в плановом порядке и по эпидемическим показаниям .Плановым прививкам подлежат: лица, работающие с живыми культурами возбудителя сибирской язвы, с зараженными лабораторными животными или производящие исследования материалов, зараженных возбудителем сибирской язвы;      лица, производящие убой скота, занятые заготовкой, сбором, хранением, транспортировкой, переработкой и реализацией сырья животного происхождения;      лица, выполняющие следующие работы на энзоотичных по сибирской язве территориях:      обслуживание общественного скота;      сельскохозяйственные, агро- и гидромелиоративные, строительные и другие работы, связанные с выемкой и перемещением грунта;      заготовительные, промысловые, геологические, изыскательные, экспедиционные."
RUS,Russian Federation,EURO,2023.0,ANTHRAX,Anthrax vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+М1,"Специфическая профилактика сибирской язвы  проводится  с 14-летнего возраста. Вакцинацию проводят в плановом порядке и по эпидемическим показаниям .Плановым прививкам подлежат: лица, работающие с живыми культурами возбудителя сибирской язвы, с зараженными лабораторными животными или производящие исследования материалов, зараженных возбудителем сибирской язвы;      лица, производящие убой скота, занятые заготовкой, сбором, хранением, транспортировкой, переработкой и реализацией сырья животного происхождения;      лица, выполняющие следующие работы на энзоотичных по сибирской язве территориях:      обслуживание общественного скота;      сельскохозяйственные, агро- и гидромелиоративные, строительные и другие работы, связанные с выемкой и перемещением грунта;      заготовительные, промысловые, геологические, изыскательные, экспедиционные."
RUS,Russian Federation,EURO,2023.0,ANTHRAX,Anthrax vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y1-Y2,"Специфическая профилактика сибирской язвы  проводится  с 14-летнего возраста. Вакцинацию проводят в плановом порядке и по эпидемическим показаниям .Плановым прививкам подлежат: лица, работающие с живыми культурами возбудителя сибирской язвы, с зараженными лабораторными животными или производящие исследования материалов, зараженных возбудителем сибирской язвы;      лица, производящие убой скота, занятые заготовкой, сбором, хранением, транспортировкой, переработкой и реализацией сырья животного происхождения;      лица, выполняющие следующие работы на энзоотичных по сибирской язве территориях:      обслуживание общественного скота;      сельскохозяйственные, агро- и гидромелиоративные, строительные и другие работы, связанные с выемкой и перемещением грунта;      заготовительные, промысловые, геологические, изыскательные, экспедиционные."
RUS,Russian Federation,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M3,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4.5,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,"Прививки «АДС»-анатоксином проводят в случае, если ребенок имеет противопоказания к применению вакцины АКДС, содержащей коклюшный компонент."
RUS,Russian Federation,EURO,2023.0,DTAPHIBIPV,DTaP-Hib-IPV (acellular) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,"В соответствии с Национальным календарем профилактических прививок Российской Федерации курс первичной вакцинации состоит из 3-х доз вакцины, вводимых с интервалом в 1.5 мес: ревакцинацию проводят однократно в возрасте 18 месяцев"
RUS,Russian Federation,EURO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,Прививки АКДС-вакциной проводят в возрасте от 3 месяцев до достижения возраста 3 года 11 мес 29 дней.Дети с противопоказаниями к применению АКДС-вакцины могут быть привиты АДС-анатоксином.
RUS,Russian Federation,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,HW,Health workers,SUBNATIONAL,1st contact,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,HW,Health workers,SUBNATIONAL,+M6-M12,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6-M12,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,1st contact,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023.0,HEPA_ADULT,Adult Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+M6-M12,"Иммунизация проводится лицам, проживающим в регионах, неблагополучных по заболеваемости вирусным гепатитом А, а также лицам, подверженные профессиональному риску заражения (медицинские работники, работники сферы обслуживания населения, занятые на предприятиях пищевой промышленности, а также обслуживающие водопроводные и канализационные сооружения, оборудование и сети).  Лица, выезжающие в неблагополучные страны (регионы), где регистрируется вспышечная заболеваемость вирусным гепатитом А. Контактные лица в очагах вирусного гепатита А.  По эпидемическим показаниям прививки проводятся при угрозе возникновения эпидемии или вспышки вирусного гепатита А (стихийные бедствия, крупные аварии на водопроводной и канализационной сети)."
RUS,Russian Federation,EURO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+M6-M12,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,1st contact,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023.0,HEPA_PEDIATRIC,Pediatric Hepatitis A vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+M6-M12,"Иммунизация показана детям в возрасте с 12 мес., проживающим в регионах, неблагополучных по ГА, в очагах ГА и выезжающим в неблагополучные страны"
RUS,Russian Federation,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Иммунизации против ВГВ подлежат взрослые с 18-55 лет,  не привитые ранее против гепатита В"
RUS,Russian Federation,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Иммунизации против ВГВ подлежат взрослые с 18-55 лет,  не привитые ранее против гепатита В"
RUS,Russian Federation,EURO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Иммунизации против ВГВ подлежат взрослые с 18-55 лет,  не привитые ранее против гепатита В"
RUS,Russian Federation,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,SUBNATIONAL,Y12-Y14,"12-14 лет девочки; Рекомендуемый курс вакцинации состоит из 3 доз и проводится по схеме (0-2-6 мес): первая доза – в назначенный день; вторая доза – через 2 мес после первой; третья доза – через 6 мес после первой. Данный вид прививки не включен в национальный календарь профилактических прививок, вакцина может закупаться за средства региональных бюджетов или непосредственно гражданами."
RUS,Russian Federation,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,SUBNATIONAL,+M2,"12-14 лет девочки; Рекомендуемый курс вакцинации состоит из 3 доз и проводится по схеме (0-2-6 мес): первая доза – в назначенный день; вторая доза – через 2 мес после первой; третья доза – через 6 мес после первой. Данный вид прививки не включен в национальный календарь профилактических прививок, вакцина может закупаться за средства региональных бюджетов или непосредственно гражданами."
RUS,Russian Federation,EURO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,3.0,FEMALE,HPV for females only,SUBNATIONAL,+M6,"12-14 лет девочки; Рекомендуемый курс вакцинации состоит из 3 доз и проводится по схеме (0-2-6 мес): первая доза – в назначенный день; вторая доза – через 2 мес после первой; третья доза – через 6 мес после первой. Данный вид прививки не включен в национальный календарь профилактических прививок, вакцина может закупаться за средства региональных бюджетов или непосредственно гражданами."
RUS,Russian Federation,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=Y60
RUS,Russian Federation,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),5.0,RISKGROUPS,Risk group(s),NATIONAL,M20,"В Российской Федерации с 2022 года введен новый национальный календарь профилактических прививок, который предусматривает  иммунизацию против полиомиелита вакциной ИПВ с 1-4 дозу, а также детям из групп риска 5-6 дозу т.е  в возрасте 20 мес и 6 лет."
RUS,Russian Federation,EURO,2023.0,IPV,IPV (Inactivated polio vaccine),6.0,RISKGROUPS,Risk group(s),NATIONAL,Y6,"В Российской Федерации с 2022 года введен новый национальный календарь профилактических прививок, который предусматривает  иммунизацию против полиомиелита вакциной ИПВ с 1-4 дозу, а также детям из групп риска 5-6 дозу т.е  в возрасте 20 мес и 6 лет."
RUS,Russian Federation,EURO,2023.0,MEASLES,Measles vaccine,3.0,ADULTS,Adults,NATIONAL,Y18-Y35,"С 18-35 все, с 36 до 55 группы риска"
RUS,Russian Federation,EURO,2023.0,MEASLES,Measles vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y36-Y55,"С 18-35 все, с 36 до 55 группы риска"
RUS,Russian Federation,EURO,2023.0,MEN_A_PS,Meningococcal A polysaccharide vaccine,1.0,ADULTS,Adults,SUBNATIONAL,>Y18,"Вакцинация детей старше 1 года, подростков и взрослых:  в очагах менингококковой инфекции, вызванной менингококками серогруппы А; в эндемичных районах, а также в случае эпидемии, вызванной менингококками серогруппы А; вакцинация лиц, подлежащих призыву на военную службу."
RUS,Russian Federation,EURO,2023.0,MEN_A_PS,Meningococcal A polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,>Y1,"Вакцинация детей старше 1 года, подростков и взрослых:  в очагах менингококковой инфекции, вызванной менингококками серогруппы А; в эндемичных районах, а также в случае эпидемии, вызванной менингококками серогруппы А; вакцинация лиц, подлежащих призыву на военную службу."
RUS,Russian Federation,EURO,2023.0,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,1.0,ADULTS,Adults,SUBNATIONAL,Y18-Y60,"Вакцинация взрослых от 18 до 60 лет:  - в очагах менингококковой инфекции, вызванной менингококками серогрупп А или С;  - в эндемичных регионах, а также в случае эпидемии, вызванной менингококками серогрупп А или С;  - вакцинация лиц, подлежащих призыву на военную службу."
RUS,Russian Federation,EURO,2023.0,MEN_AC_PS,Meningococcal AC polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,>Y18,"Вакцинация взрослых от 18 до 60 лет:  - в очагах менингококковой инфекции, вызванной менингококками серогрупп А или С;  - в эндемичных регионах, а также в случае эпидемии, вызванной менингококками серогрупп А или С;  - вакцинация лиц, подлежащих призыву на военную службу."
RUS,Russian Federation,EURO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"по эпидпоказаниям, для паломников, детей в рамках региональных календарей профилактических прививок. В региональных календарях подлежат дети  в возрасте с 3-6 лет перед поступлением в детские дошкольные образовательные организации ."
RUS,Russian Federation,EURO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y3,"по эпидпоказаниям, для паломников, детей в рамках региональных календарей профилактических прививок. В региональных календарях подлежат дети  в возрасте с 3-6 лет перед поступлением в детские дошкольные образовательные организации ."
RUS,Russian Federation,EURO,2023.0,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023.0,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+D7,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023.0,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+D30,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023.0,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y1,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023.0,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y3,"С профилактической целью иммунизируют лиц, имеющих высокий риск заражения бешенством (сотрудники лабораторий, работающие с уличным вирусом бешенства; ветеринарные работники; егеря, охотники, лесники; лица, выполняющие работы по отлову и содержанию животных и другие профессиональные группы)"
RUS,Russian Federation,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+М1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,3.0,ADULTS,Adults,SUBNATIONAL,+Y1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,4.0,ADULTS,Adults,SUBNATIONAL,+Y3,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,4.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y3,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,3.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+М1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,1st contact,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,1st contact,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+М1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,3.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y1,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TBE_PEDIATRIC,Pediatric TBE (tick borne encephalitis) vaccine,4.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y3,"для населения, проживающего на эндемичных территориях или выезжающих в эндемичные регионы"
RUS,Russian Federation,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y24,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_CHILD_W,General/routine,NATIONAL,Y6-Y7,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,B_ADO_W,General/routine,NATIONAL,Y14,"Вакцина предназначена для профилактики дифтерии у детей с 6-ти летнего возраста, подростков и взрослых."
RUS,Russian Federation,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,>Y6,В региональных календарях иммунизации  подлежат дети с  6-летнего  возраста и взрослые.
RUS,Russian Federation,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Активная иммунизация препаратом АС  проводится у лиц, ранее не привитых против столбняка, в т.ч. по эпидемическим показаниям (травмы и тд.)."
RUS,Russian Federation,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6-M12,"Активная иммунизация препаратом АС  проводится у лиц, ранее не привитых против столбняка, в т.ч. по эпидемическим показаниям (травмы и тд.)."
RUS,Russian Federation,EURO,2023.0,TULAREMIA,Tularemia vaccine,1.0,ADULTS,Adults,SUBNATIONAL,1st contact,"Иммунизация против туляремии проводится с 7-летнего возраста (с 14 лет - в очагах полевого типа).  Прививкам подлежит население, проживающее на энзоотичных по туляремии территориях, а также прибывшие на эти территории лица, выполняющие следующие работы:  сельскохозяйственные; гидромелиоративные; строительные; другие работы по выемке и перемещению грунта; заготовительные; промысловые; геологические; изыскательные; экспедиционные; дератизационные и дезинсекционные; по лесозаготовке, расчистке и благоустройству леса, зон оздоровления и отдыха населения."
RUS,Russian Federation,EURO,2023.0,TULAREMIA,Tularemia vaccine,2.0,ADULTS,Adults,SUBNATIONAL,+Y5,"Иммунизация против туляремии проводится с 7-летнего возраста (с 14 лет - в очагах полевого типа).  Прививкам подлежит население, проживающее на энзоотичных по туляремии территориях, а также прибывшие на эти территории лица, выполняющие следующие работы:  сельскохозяйственные; гидромелиоративные; строительные; другие работы по выемке и перемещению грунта; заготовительные; промысловые; геологические; изыскательные; экспедиционные; дератизационные и дезинсекционные; по лесозаготовке, расчистке и благоустройству леса, зон оздоровления и отдыха населения."
RUS,Russian Federation,EURO,2023.0,TULAREMIA,Tularemia vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,"Иммунизация против туляремии проводится с 7-летнего возраста (с 14 лет - в очагах полевого типа).  Прививкам подлежит население, проживающее на энзоотичных по туляремии территориях, а также прибывшие на эти территории лица, выполняющие следующие работы:  сельскохозяйственные; гидромелиоративные; строительные; другие работы по выемке и перемещению грунта; заготовительные; промысловые; геологические; изыскательные; экспедиционные; дератизационные и дезинсекционные; по лесозаготовке, расчистке и благоустройству леса, зон оздоровления и отдыха населения."
RUS,Russian Federation,EURO,2023.0,TULAREMIA,Tularemia vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y5,"Иммунизация против туляремии проводится с 7-летнего возраста (с 14 лет - в очагах полевого типа).  Прививкам подлежит население, проживающее на энзоотичных по туляремии территориях, а также прибывшие на эти территории лица, выполняющие следующие работы:  сельскохозяйственные; гидромелиоративные; строительные; другие работы по выемке и перемещению грунта; заготовительные; промысловые; геологические; изыскательные; экспедиционные; дератизационные и дезинсекционные; по лесозаготовке, расчистке и благоустройству леса, зон оздоровления и отдыха населения."
RUS,Russian Federation,EURO,2023.0,TYPHOID_PS,Typhoid polysaccharide vaccine,1.0,RISKGROUPS,Risk group(s),SUBNATIONAL,1st contact,Для групп риска ревакцинация каждые 3 года
RUS,Russian Federation,EURO,2023.0,TYPHOID_PS,Typhoid polysaccharide vaccine,2.0,RISKGROUPS,Risk group(s),SUBNATIONAL,+Y3,Для групп риска ревакцинация каждые 3 года
RUS,Russian Federation,EURO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,SUBNATIONAL,>М9,для выезжающих в эндемичные страны
RUS,Russian Federation,EURO,2023.0,YF,YF (Yellow fever) vaccine,2.0,TRAVELLERS,Travellers,SUBNATIONAL,+Y10,для выезжающих в эндемичные страны
RWA,Rwanda,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y12,12 years old females
RWA,Rwanda,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,12 years old females
RWA,Rwanda,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
RWA,Rwanda,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
RWA,Rwanda,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
RWA,Rwanda,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
RWA,Rwanda,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
SAU,Saudi Arabia,EMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,<Y7,DTP contrindicated
SAU,Saudi Arabia,EMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons 50Y
SAU,Saudi Arabia,EMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,+D30,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023.0,MMR,"MMR (Measles, mumps and rubella) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,Y18,Premarital and postnatal females (+30 days)
SAU,Saudi Arabia,EMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,Y18,High risk groups
SAU,Saudi Arabia,EMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y50,50 years and above
SAU,Saudi Arabia,EMRO,2023.0,ZOSTER,Shingles (Herpes zoster for older adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M2-M6,50 years and above
SDN,Sudan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
SDN,Sudan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women
SDN,Sudan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
SDN,Sudan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SDN,Sudan,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SEN,Senegal,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,filles de 9-14 ans
SEN,Senegal,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,filles de 9-14 ans
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SEN,Senegal,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,La cible pour le PEV est  les Femmes enceintes. Cependant les autres cibles bénéficient aussi de la vaccination car la série vaccinale est poursuivie aprés l'accouchement. De même les autres femmes en  âge de reproduction  aussi vaccinées
SGP,Singapore,WPRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y13,females
SGP,Singapore,WPRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y14,females
SLB,Solomon Islands,WPRO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,Females
SLB,Solomon Islands,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact pregnancy
SLB,Solomon Islands,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact pregnancy
SLB,Solomon Islands,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact pregnancy
SLB,Solomon Islands,WPRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact pregnancy
SLE,Sierra Leone,AFRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,Females upon 1st contact
SLE,Sierra Leone,AFRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females upon 1st contact
SLE,Sierra Leone,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,WCBA
SLE,Sierra Leone,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,WCBA
SLE,Sierra Leone,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,WCBA
SLE,Sierra Leone,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,WCBA
SLE,Sierra Leone,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,WCBA
SLV,El Salvador,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",4.0,RISKGROUPS,Risk group(s),NATIONAL,M15-M18,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,RISKGROUPS,Risk group(s),NATIONAL,Y4,Niños que por alguna contraindicaicón no pudieron recibir la Pentavalente
SLV,El Salvador,AMRO,2023.0,DTWP,DTwP (Whole cell) vaccine,5.0,B_CHILD_W,General/routine,NATIONAL,Y4,Segundo refuerzo a los 4 años
SLV,El Salvador,AMRO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M15-M18,"1° dosis a los 2 meses, 2° dosis a los 4 meses y 3° dosis a los 6 meses de edad, se utilizo como refuerzo a los 18 meses hasta el mes de julio 2023"
SLV,El Salvador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Personal de salud
SLV,El Salvador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Personal de salud
SLV,El Salvador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Personal de salud
SLV,El Salvador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"Personal de riesgo y con enfermedades cronicas, se aplica en adultos la primera dosis posteriormente al mes de la primera dosis y posteriormente a los seis meses en donde se completa el esquema"
SLV,El Salvador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"Personal de riesgo y con enfermedades cronicas, se aplica en adultos la primera dosis posteriormente al mes de la primera dosis y posteriormente a los seis meses en donde se completa el esquema"
SLV,El Salvador,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Personal de riesgo y con enfermedades cronicas, se aplica en adultos la primera dosis posteriormente al mes de la primera dosis y posteriormente a los seis meses en donde se completa el esquema"
SLV,El Salvador,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9,niñas de 9 años
SLV,El Salvador,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,niñas de 9 años
SLV,El Salvador,AMRO,2023.0,PCV13,PCV-13 (Pneumococcal conjugate vaccine 13-valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,"Personas  con enfermedades cronicas de alto riesgo , mayores de 60 años de edad"
SLV,El Salvador,AMRO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y60,"Adultos  Mayores de 60 años, Grupos de riesgo y personas con enfermedades cronicas"
SLV,El Salvador,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,B_ADO_W,General/routine,NATIONAL,Y10,niños de 10 año de edad
SLV,El Salvador,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=Y1,"una dosis a los Viajeros a países endemicos, a partir del  1 año de edad"
SMR,San Marino,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administered to newborns of HBSaG positive mothers
SMR,San Marino,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11-Y14,Females
SMR,San Marino,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females
SMR,San Marino,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",1.0,ADULTS,Adults,NATIONAL,Y25,Adults every 10 years
SMR,San Marino,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",2.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",3.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",4.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",6.0,ADULTS,Adults,NATIONAL,+Y10,Adults every 10 years
SMR,San Marino,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,Y25,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,2.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,3.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SMR,San Marino,EURO,2023.0,TT,TT (Tetanus toxoid) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Every 10 years to individuals that refuse TdaP
SOM,Somalia,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,pregnant women
SOM,Somalia,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,pregnant women
SOM,Somalia,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,pregnant women
SOM,Somalia,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
SOM,Somalia,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,pregnant women
SRB,Serbia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y9-Y19,"Recommended HPV 9 vaccine is free of charge (funded by National Health Insurance Fund) for children of both genders aged 9 to 19 years. The number of doses depends on age: two dose schedule (0, 6 months) is predicted for children aged 9 to 14 years while three dose schedule is predicted for children aged 15 to 19 years (regimen 0, 2, 6 months)."
SRB,Serbia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M6,"Recommended HPV 9 vaccine is free of charge (funded by National Health Insurance Fund) for children of both genders aged 9 to 19 years. The number of doses depends on age: two dose schedule (0, 6 months) is predicted for children aged 9 to 14 years while three dose schedule is predicted for children aged 15 to 19 years (regimen 0, 2, 6 months)."
SSD,South Sudan,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,15-45 years
SSD,South Sudan,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,15-45 years
SSD,South Sudan,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,15-45 years
SSD,South Sudan,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,15-45 years
SSD,South Sudan,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,15-45 years
STP,Sao Tome and Principe,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes
STP,Sao Tome and Principe,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y2,femmes enceintes
SUR,Suriname,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M2,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M4,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,M6,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023.0,DTAP,DTaP (acellular) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,M18,Children hypersensitive to whole cell pertussis vaccine
SUR,Suriname,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,Given to health care workers and those at high risk
SUR,Suriname,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,For those unable to receive penta
SUR,Suriname,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,For those unable to receive penta
SUR,Suriname,AMRO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,For those unable to receive penta
SUR,Suriname,AMRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y9-Y13,Females
SUR,Suriname,AMRO,2023.0,HPV2,HPV-2 (Human Papilloma Virus 2-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,Females
SUR,Suriname,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Travellers, high risk individuals"
SUR,Suriname,AMRO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Travellers, high risk individuals"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+D3,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+D7,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+D14,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+D28,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,5.0,TRAVELLERS,Travellers,NATIONAL,+D28,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,4.0,TRAVELLERS,Travellers,NATIONAL,+D14,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,3.0,TRAVELLERS,Travellers,NATIONAL,+D7,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+D3,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,RABIES,Rabies vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,1st contact,"Travellers to the interior, response to animal bites"
SUR,Suriname,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,Pregnant women and others at risk without vaccination
SUR,Suriname,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,Pregnant women and others at risk without vaccination
SVK,Slovakia,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Administered only to high risk groups (newborns of HepB positive mothers)
SVK,Slovakia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y12,12-14 years old girls and boys; 2nd dose of HPV is applicated 5M-13M after the first dose according to SPC for Gardasil-9; vaccine is not part of the regular mandatory vaccination but just recommended free of charge vaccination
SVK,Slovakia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,+M5-M13,12-14 years old girls and boys; 2nd dose of HPV is applicated 5M-13M after the first dose according to SPC for Gardasil-9; vaccine is not part of the regular mandatory vaccination but just recommended free of charge vaccination
SVK,Slovakia,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons >=59 years
SVK,Slovakia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,Y30,Vaccination in adults when reaching 30 years and than the revaccination every 15 years
SVK,Slovakia,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,7.0,ADULTS,Adults,NATIONAL,+Y15,Vaccination in adults when reaching 30 years and than the revaccination every 15 years
SVN,Slovenia,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,Epidemiological indications
SVN,Slovenia,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"HepBBD only administered to newborns of HBsAG positive mothers, simultaneously with immunoglobulin against Hepatitis B"
SVN,Slovenia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,Females; in the 6th grade of elementary school; males in 6th grade of elementary school from September 2021
SVN,Slovenia,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y12,Females; in the 6th grade of elementary school; males in 6th grade of elementary school from September 2021
SVN,Slovenia,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65 years of age or more
SVN,Slovenia,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,>Y65,"Risk groups, older persons from 65 years"
SVN,Slovenia,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,1.0,ADULTS,Adults,NATIONAL,Y49,Adults
SVN,Slovenia,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1-M3,Adults
SVN,Slovenia,EURO,2023.0,TBE_ADULT,Adult TBE (tick borne encephalitis) vaccine,3.0,ADULTS,Adults,NATIONAL,+M5-M12,Adults
SVN,Slovenia,EURO,2023.0,TDAP_S,"Tdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine",5.0,B_ADO_F,General/routine,NATIONAL,Y8,5th dose for children who were vaccinated with DTaP-Hib-IPV
SWE,Sweden,EURO,2023.0,BCG,BCG (Baccille Calmette Guérin) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,W6-M6,Risk groups
SWE,Sweden,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,B,"Children to HBsAg+ mothers (following doses are given as DTP-IPV-Hib-HepB at M3, M5 and M12)"
SWE,Sweden,EURO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,"Children to HBsAg+ mothers (following doses are given as DTP-IPV-Hib-HepB at M3, M5 and M12)"
SWE,Sweden,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y10-Y11,Both females and males
SWE,Sweden,EURO,2023.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,BOTH,HPV administered to females and males,NATIONAL,Y11-Y12,Both females and males
SWE,Sweden,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,ADULTS,Adults,NATIONAL,Y75,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWE,Sweden,EURO,2023.0,PPV23,PPV-23 (Pneumococcal polysaccharide 23 valent) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,>=Y65,Medical risk groups and persons at age 75 yrs are offered vaccination within the NIP. PPV23 is recommended to risk groups with increased risk for IPD Vaccinaton with PPV23 is also recommended to all persons 65 years and older
SWZ,Eswatini,AFRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y5,5 Y - 9 Y
SWZ,Eswatini,AFRO,2023.0,DTWPHIBHEPB,DTwP-Hib-HepB (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,6 W - 23 M
SWZ,Eswatini,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,Health care workers
SWZ,Eswatini,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+W4,Health care workers
SWZ,Eswatini,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+W4,Health care workers
SWZ,Eswatini,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,"Armed forces, Fire fighters,"
SWZ,Eswatini,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+W4,"Armed forces, Fire fighters,"
SWZ,Eswatini,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"Armed forces, Fire fighters,"
SWZ,Eswatini,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
SWZ,Eswatini,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+W4,Pregnant women
SWZ,Eswatini,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,Pregnant women
SWZ,Eswatini,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SWZ,Eswatini,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SWZ,Eswatini,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,PW,Pregnant women,NATIONAL,+Y1,Pregnant women
SXM,Sint Maarten (Dutch part),AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M7,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,for risk group adults and children over 55kg
SXM,Sint Maarten (Dutch part),AMRO,2019.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,+M6,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019.0,HPV9,HPV-9 (Human Papilloma Virus 9-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y9-Y11,females in primary school; switched to nonavalent in 2018
SXM,Sint Maarten (Dutch part),AMRO,2019.0,YF,YF (Yellow fever) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,travellers to endemic countries
SYC,Seychelles,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,high risk
SYC,Seychelles,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,high risk
SYC,Seychelles,AFRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,high risk
SYC,Seychelles,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y10,females; P6
SYC,Seychelles,AFRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,Y11,females; P6
SYC,Seychelles,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y25,pregnant women and other adults every 10 years
SYC,Seychelles,AFRO,2023.0,TT,TT (Tetanus toxoid) vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y25,pregnant women and other adults every 10 years
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,1st contact,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+M1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,RISKGROUPS,Risk group(s),NATIONAL,+M6,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"For adults, pregnant women & risk groups"
SYR,Syrian Arab Republic,EMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,RISKGROUPS,Risk group(s),NATIONAL,+Y1,"For adults, pregnant women & risk groups"
TCA,Turks and Caicos Islands,AMRO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,CATCHUP_C,Catch-up children,NATIONAL,Y7-Y11,Given to children age 7 to 10 years who missed doses
TCA,Turks and Caicos Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,>=Y15,1st contact from >=15 years who missed their childhood doses
TCA,Turks and Caicos Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,1st contact from >=15 years who missed their childhood doses
TCA,Turks and Caicos Islands,AMRO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,1st contact from >=15 years who missed their childhood doses
TCA,Turks and Caicos Islands,AMRO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,BOTH,HPV administered to females and males,NATIONAL,Y11,"Quadrivalent vaccine for girls 9+ years, but focus on 11 year old girls up to 26 years old women. The first HPV vaccine was bivalent and it was introduced on February 1st 2019 to girls only.  The quadrivalent is being to administered to both male and females."
TCA,Turks and Caicos Islands,AMRO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,CATCHUP_A,Catch-up adults,NATIONAL,1st contact,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_A,Catch-up adults,NATIONAL,+M1,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_A,Catch-up adults,NATIONAL,+M6,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,CATCHUP_C,Catch-up children,NATIONAL,+M1,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,CATCHUP_C,Catch-up children,NATIONAL,+M6,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,CATCHUP_C,Catch-up children,NATIONAL,1st contact,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Persons 15 years and older with missed doses in childhood and pregnant women. After initial dose; doses are given at 4 weeks, 6 months"
TCA,Turks and Caicos Islands,AMRO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=M9,Only for travelers to endemic countries. Can be administered to travelers as young as 9/12
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,femmes enceintes et femmes en âge de procréer
TCD,Chad,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,femmes enceintes et femmes en âge de procréer
TGO,Togo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse - femmes enceintes
TGO,Togo,AFRO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,PW,Pregnant women,NATIONAL,+Y1,1st contact grossesse - femmes enceintes
THA,Thailand,SEARO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,1.0,HW,Health workers,NATIONAL,1st contact,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,2.0,HW,Health workers,NATIONAL,+M1,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023.0,HEPB_ADULT,Adult Hepatitis B vaccine,3.0,HW,Health workers,NATIONAL,+M6,"Healthcare workers (HCWs), Booster dose birth > 1993 1st contact"
THA,Thailand,SEARO,2023.0,HEPB_PEDIATRIC,Pediatric Hepatitis B vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,M1,Given at 1 month for children with carrier mother
THA,Thailand,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,1.0,FEMALE,HPV for females only,NATIONAL,Y11,"Female students grade 5, 2 doses - 6 months apart"
THA,Thailand,SEARO,2023.0,HPV4,HPV-4 (Human Papilloma Virus 4-valent) vaccine,2.0,FEMALE,HPV for females only,NATIONAL,+M6,"Female students grade 5, 2 doses - 6 months apart"
THA,Thailand,SEARO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>Y18,and older persons 65Y+
THA,Thailand,SEARO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,RISKGROUPS,Risk group(s),NATIONAL,M9-Y55,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,RISKGROUPS,Risk group(s),NATIONAL,+Y5,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,M9-Y55,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023.0,MEN_ACYW_135CONJ,Meningococcal ACYW conjugate vaccine,2.0,TRAVELLERS,Travellers,NATIONAL,+Y5,"Travellers, and if greater than 55 years they should be certified by their physicians"
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,ADULTS,Adults,NATIONAL,1st contact,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,+M1,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,+M6,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,+Y10,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,+Y10,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,6.0,ADULTS,Adults,NATIONAL,+Y10,Adult age 20Y above booster dose every 10 years
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_W,General/routine,NATIONAL,Y12,All school children in grade 6
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,PW,Pregnant women,NATIONAL,+M6,"Adult age 20Y above booster dose every 10 years, Pregnant women at 1st contact, +1 month, +6 months (depending on vaccination history)"
THA,Thailand,SEARO,2023.0,YF,YF (Yellow fever) vaccine,1.0,TRAVELLERS,Travellers,NATIONAL,>=M9,Travellers
TJK,Tajikistan,EURO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",1.0,B_CHILD_W,General/routine,NATIONAL,Y6,Дети 6 лет
TJK,Tajikistan,EURO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,М16-M23,Дети 16-23 месяца
TJK,Tajikistan,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,ADULTS,Adults,NATIONAL,Y26,Взрослые  в возрасте 16-26-36-46-56 лет.
TJK,Tajikistan,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,3.0,ADULTS,Adults,NATIONAL,Y36,Взрослые  в возрасте 16-26-36-46-56 лет.
TJK,Tajikistan,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,4.0,ADULTS,Adults,NATIONAL,Y46,Взрослые  в возрасте 16-26-36-46-56 лет.
TJK,Tajikistan,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,5.0,ADULTS,Adults,NATIONAL,Y56,Взрослые  в возрасте 16-26-36-46-56 лет.
TJK,Tajikistan,EURO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,B_ADO_F,General/routine,NATIONAL,Y16,Взрослые  в возрасте 16-26-36-46-56 лет.
TKM,Turkmenistan,EURO,2023.0,INFLUENZA_ADULT,Adult seasonal influenza vaccine,1.0,ADULTS,Adults,NATIONAL,>=Y18,and older persons 65+
TLS,Timor-Leste,SEARO,2023.0,DT,"DT (Tetanus toxoid and diphtheria, children's dose) vaccine",5.0,B_CHILD_W,General/routine,NATIONAL,Y6,6Y
TLS,Timor-Leste,SEARO,2023.0,DTWP,DTwP (Whole cell) vaccine,4.0,B_2YL_W,General/routine,NATIONAL,M18,1-2Y
TLS,Timor-Leste,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,1.0,PW,Pregnant women,NATIONAL,1st contact,Pregnant women
TLS,Timor-Leste,SEARO,2023.0,TD_S,Td (Tetanus toxoid and diphtheria for older children and adults) vaccine,2.0,PW,Pregnant women,NATIONAL,+M1,Pregnant women